TSCA HEALTH & SAFETY STUDY COVER SHEET

TSCA CBI STATUS:

-CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)

Clearly mark the confidential information with bracketing and check the box in the appropriate section (☐ *Contains CBI*).
Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

1.0 SUBMISSION TYPE - *Contains CBI*

☐ 8(d) **X 8(e)** ☐ FYI ☐ 4 ☐ OTHER: Specify 8EHQ-0699-14491

XX- Intial Submission -Follow-up Submission ☐ Final Report Submission

Previous EPA Submission Number or Title if update or follow-up:

Docket Number, if any: #

☐ continuation sheet attached

2.1 SUMMARY/ABSTRACT ATTACHED (may be required for 8(e): optional for §4, 8(d) & FYI)	**2.2 SUBMITTER TRACKING NUMBER OR INTERNAL ID**	**2.3 FOR EPA USE ONLY**
X - YES ☐ NO	Cert# P 917006915 99-2-44	

3.0 CHEMICAL/TEST SUBSTANCE IDENTITY -*Contains CBI*

Reported Chemical Name (specify nomenclature if other than CAS name):

CAS#: 120983-64-4 2-(1-Chlorcyclopropyl)-1-(2-chlorphenyl) = -3-(1,2,4-triazol-1-yl)-propan-2-ol

Purity _____%

☐ - Single Ingredient

☐ Commerical/Tech Grade

☐-Mixture *Trade Name:* SXX 0665 *Common Name:* ____

CONTAINS NO CBI

4.0 REPORT/STUDY TITLE - *Contains CBI*

Embryotoxicity Study (Including Teratogenicity) Technical in the Rat, Part 1 – RCC No. 236114, Report # R5436

☐ Continuation sheet attached

5.1 STUDY/TSCATS INDEXING TERMS

[CHECK ONE]

HEALTH EFFECTS (HE): X ENVIRONMENTAL EFFECTS (EE): ____ ENVIRONMENTAL FATE (EF): ____

5.2 STUDY/TSCATS INDEXING TERMS (see instructions for 4 digit codes)

STUDY TYPE: TOX *Other:* ____

SUBJECT ORGANISM (HE, EE only): RATS Other: ____

ROUTE OF EXPOSURE (HE only): ____ *Other:* ____

VEHICLE OF EXPOSURE (HEonly) ____ *Other:* ____

6.0 REPORT/STUDY INFORMATION ☐ *Contains CBI* ☐ Study is GLP

Laboratory RCC Research & Consulting Company AG Report/Study Date: 12/11/91

Source of Data/Study Sponsor (if different than submitter) Bayer AG Number of pages : 324

☐ continuation sheet attached

7.0 SUBMITTER INFORMATION ☐ *Contains CBI*

Submitter: Donald W. Lamb, Ph.D Title: V. P., Prod. Safety & Reg. Affrs Phone: 412-777-7431

Company Name: Bayer Corporation Company Address: 100 Bayer Road

Pittsburgh, PA 15205-9741 Submitter Address (if different): ____

Technical Contact: Donald W. Lamb, Ph.D Phone: (412)777-7431

☐ continuation sheet attached

8.0 ADDITIONAL/OPTIONAL STUDY COMMENTS ☐ *Contains CBI*

SXX 0665 is a metabolite of toxicological concern for a compound (JAU 6476) which is under development as a fungicide.

☐ continuation sheet attached

Submitter Signature: Donald W Lamb **Date:** 6/23/99

Page 1

8EHQ-99-14491

88990000210

1999 JUN 30 PM 12:52 OPPT RECEIVED

99 JUL 29 AM 7:50 OPPT RCIC

9.0 CONTINUATION SHEET

TSCA CBI STATUS:

☐ **CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)**

Clearly mark the confidential information with bracketing and check the box in the appropriate section (☐ *Contains CBI*). Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

Submitter Tracking Number/Internal ID

P917006915
99-2-44

CONTINUED FROM COVER SHEET SECTION #_____2.1_____

SXX 0665 is a compound which was under development as a potential fungicide, but development of this compound was ceased due to the toxicity profile of the compound. A related fungicide, JAU 6476 is presently under development, and it has been shown that JAU 6476 breaks down to SXX 0665, upon drying, after application to plants/seeds, and upon administration to test animals. (Note: The extent of breakdown varies considerably based on the plant/seed to which JAU 6476 is applied). However, as JAU 6476 has fungicide properties, and the development of JAU 6476 as a fungicide is not based on the conversion of JAU 6476 to SXX 0665, JAU 6476 is not considered to be a delivery system for applying SXX 0665 to plants/seeds. Therefore, although SXX 0665 does have fungicide activity and may be of toxicological concern for evaluating risk assessment and in determining RFD values for JAU 6476, SXX 0665 is strictly a metabolite of JAU 6476 and is not a compound which is being developed for commercial use. Thus, SXX 0665 is not regulated by TSCA 8(e) Adverse Effects Regulations. However, as SXX 0665 is a metabolite of toxicological concern for a compound (i.e., JAU 6476) which is under development as a fungicide, and this study contains data that triggers reporting (i.e., there was an increase in post-implantation loss in the 100 mg/kg dose group, with a corresponding decrease in litter size, and increase in the number of supernumerary ribs in the 10, 30, and 100 mg/kg dose groups), this study is being reported.

Abstract

The purpose of this study was to assess the effects of SXX 0665 on embryonic and fetal development in pregnant Wistar/HAN rats.

Each group consisted of 25 mated female rats. SXX 0665 was administered orally by gavage once daily from day 6 through to day 15 post coitus, at dose levels of:

Group 1: 0 mg/kg body weight/day
(vehicle control)
Group 2: 10 mg/kg body weight/day
Group 3: 30 mg/kg body weight/day
Group 4: 100 mg/kg body weight/day

A standard dose volume of 10 ml/kg body weight, with a daily adjustment to the actual body weight, was used. Control animals were dosed with the vehicle alone (bi-distilled water with 0.5 % Cremophor EL).

Females were sacrificed on day 21 post coitus, and the fetuses were removed by Caesarean section. The examination of the dams and fetuses was performed in accordance with international recommendations.

Submitter Tracking Number/Internal ID

P917006915
99-2-44

CONTINUED FROM COVER SHEET SECTION #____2.1_____

The following results were obtained:

GENERAL TOLERABILITY IN DAMS
- Oral administration of SXX 0665 did not influence the viability or the behavior and appearance of the animals. At necropsy, no treatment-related macroscopic changes were noted.
- Slightly reduced mean food consumption and marginally reduced mean body weight gain were noted at 100 mg/kg during the first half of the treatment period (days 6 to 11 post coitus).

REPRODUCTION PARAMETERS OF THE DAMS
- At 100 mg/kg, post-implantation loss was increased and consequently the number of live fetuses was reduced. Differences from the vehicle control group were statistically significant.
- All other differences from Control values were within the normal range of variation and considered not to be test article related effects.

FETAL PARAMETERS
- During external examination of the fetuses, three fetuses from three litters with different malformations were noted at 100 mg/kg. One fetus had palatoschisis, the second fetus had a shortened and constricted tail and the third fetus had palatoschisis, dysplastic lower jaw, arthrogryposis and most of the claws were missing.
- Fetal sex ratios and mean fetal body weights were similar in all groups.
- The visceral examination of fetuses by Wilson Technique as well as the skeletal examination of fetuses for abnormal findings gave no indication of test article-related effects.
- The examination of fetuses for the stage of skeletal development resulted in a dose-related statistically significant increase in the number of fetuses with supernumerary ribs at 10, 30, and 100 mg/kg.
- With the exception of this skeletal variant, all other differences from Control values at 10 and 30 mg/kg (although often statistically significant) were considered to be incidental as there was no trend.
- The fetuses at 100 mg/kg revealed a lower stage of ossification in several parts of the skeleton.

CONCLUSION (MAIN GROUPS)
SXX 0665 was administered by gavage to mated Wistar/HAN rats at dosages of 0, 10, 30, or 100 mg/kg body weight/day from days 6 through to day 15 post coitus in order to assess the effects of the compound on embryonic and fetal development.

At 100 mg/kg, slightly reduced food consumption and marginally reduced body weight gain were noted.

Based on these results, the no-observable adverse effect level for the maternal organism was considered to be 30 mg/kg body weight/day.

In regard to embryonic/fetal development, an increased incidence of embryonic resorption was noted at 100 mg/kg and as a consequence, the number of live fetuses was reduced. The occurrence of three malformed fetuses at 100 mg/kg was possibly incidental; however, a slight effect on fetal development was indicated by a dose-related increased incidence of supernumerary rib(s) from 10 mg/kg upwards. In consideration of the supernumerary ribs, a no-observable adverse effect level for embryonic/fetal development was not attained.

CONTINUED FROM COVER SHEET SECTION #____2.1_____

SUMMARY (SUBGROUPS)

In addition, four subgroups each consisting of ten mated females, were similarly dosed from day 6- through to day 15 post coitus. On day 16 post coitus, blood samples were collected for determination of transaminase activity. After blood collection, the subgroup females were sacrificed, pregnancy status was recorded, livers were weighed and fixed in 4% formaldehyde solution for subsequent processing and histopathological examination.

The following results were obtained:

- As noted for the females of the main groups, slightly reduced food consumption and marginally reduced body weight gain were noted at 100 mg/kg during the first half of the dosing period (days 6 to 11 post coitus).
- No further reactions to treatment were observed and no abnormal findings were noted during necropsy.
- The evaluation of the reproduction parameters resulted in a slightly increased post-implantation loss at 100 mg/kg.
- No indication of treatment-related changes were noted in any dose group for plasma transaminase activity, (ASAT and ALAT) assessed at day 16 post coitus.
- The liver weight and the liver/body weight ratio were slightly increased at 10 and 30 mg/kg and significantly increased at 100 mg/kg.
- Treatment with SXX 0665 was associated with hepatic lesions in rats of group 4 (100 mg/kg). These lesions were centrilobular hypertrophy and centrilobular/periportal fatty change. In addition, a treatment-related increase in severity of inflammatory cell foci was diagnosed in the rats of group 4 (100 mg/kg).

CONCLUSION (SUBGROUPS)

In the subgroup females of this study, the reaction to administration of the test article was similar to that noted in the females of the main groups.

Slightly reduced food consumption and body weight gain and slightly increased post-implantation loss were observed at 100 mg/kg.

From the additional parameters recorded (plasma transaminase activity, liver weights and liver pathology), an effect of treatment with SXX 0665 was observed in the increased liver weights and histopathological changes observed in the liver at 100 mg/kg body weight/day.

Based on these results, the no-observable adverse effect level for the maternal organism was considered to be 30 mg/kg body weight/day.

STUDY TITLE

Embryotoxicity Study (Including Teratogenicity)
with SXX 0665 Technical in the Rat
Report: Part I

DATA REQUIREMENT

US EPA-FIFRA Guideline No. 83-3(a)

108979

AUTHORS

Dr. H. Becker, Dr. H. Leutkemeier, Dr. K. Biedermann,
Dr. O Vogel and Dr. Ch. Terrier

FILE
8836

STUDY COMPLETION DATE

December 11, 1991

PERFORMING LABORATORY

RCC
Research and Consulting Company AG
P. O. Box CH 4452 Itingen
Switzerland

SPONSOR

BAYER AG
DEPARTMENT OF TOXICOLOGY
Friedrich-Ebert-Strasse 217-233
D-42096 Wuppertal
Germany

LABORATORY PROJECT ID

RCC Project No. 236114
Bayer AG Report No. R 5436

RCC PROJECT 236114
SXX 0665 TECHNICAL

STATEMENT OF DATA CONFIDENTIALITY

Confidential
Copyright by Bayer AG
The use, utilization or distribution
is only permitted with the consent of Bayer AG.

The following statement supercedes the above statement of confidentiality that may occur elsewhere in this report:

No claim of confidentiality is made for any information contained in this study on the basis of its falling within the scope of FIFRA Section 10(d)(1)(A), (B), or (C).

BAYER CORPORATION

Dr. J.H. Thyssen: _____
Vice President, Toxicology

Date: 4-19-99

GOOD LABORATORY PRACTICE STATEMENT

PROJECT NUMBER: 236114

TEST ARTICLE: SXX 0665 TECHNICAL

STUDY DIRECTOR: H. Becker

TITLE: Embryotoxicity Study (Including Teratogenicity) in the Rat

This study conforms to the OECD Principles of Good Laboratory Practice (GLP), the Good Laboratory Practice Guidelines for Switzerland and meets the FIFRA Good Laboratory Practice Standards (40 CFR Part 160), with the exception that recognized differences exist between the GLP principles/standards of OECD, Switzerland and FIFRA with regard to the authority granted Agency inspectors and certain record retention requirements.

Submitter: Bayer Corporation

Dr. J.H. Thyssen

.....

Date: 4-19-99

Study Director:

H. Becker

.....

date: December 17, 1991

Sponsor: Bayer AG

Dr. L. Machemer

.....

date: Dec. 12, 1991

RCC PROJECT 236114
SXX 0665 TECHNICAL

FLAGGING STATEMENT

I have applied the criteria of 40 CFR 158.34 for flagging studies for potential adverse effects to the results of the attached study. This study meets or exceeds the criteria numbered 83-3.

SUBMITTER

BAYER CORPORATION

Dr. J.H. Thyssen: _____
Vice President, Toxicology

Date: 4-28-99

SPONSOR

AGRICULTURE DIVISION

Dr. J.H. Thyssen: _____
Vice President, Toxicology

Date: 4-28-99

CONTENTS REPORT PART I

	PAGE
QUALITY ASSURANCE-UNIT STATEMENT	8
PROJECT STAFF	9
PREFACE	10
GUIDELINES	11
SUMMARY OF PROTOCOL AMENDMENTS	11
SUMMARY (MAIN GROUPS)	12
CONCLUSION (MAIN GROUPS)	13
SUMMARY (SUBGROUPS)	14
CONCLUSION (SUBGROUPS)	14
OBJECTIVE	15
MATERIALS AND METHODS	
Experimental Design	
Test System	15
Husbandry	16
Test Article	16
Procedures, Observations, Data Recording and Compilation	17
Data Processing	21
Terminology used in the Assessment of the Data	22
Archiving	22
RESULTS (MAIN GROUPS)	23
STATISTICAL ANALYSIS REPORT (MAIN GROUPS)	27
RESULTS (SUBGROUPS)	31

TABLES AND FIGURES (MAIN GROUPS)

Food Consumption of Dams post coitum - Figure	34
Food Consumption of Dams post coitum - Tables	35
Differences in Food Consumption of Dams, Mean	39
Body Weights of Dams post coitum - Figure	40
Body Weights of Dams post coitum - Tables	41

CONTENTS REPORT PART I (cont'd)

	PAGE
Corrected Body Weight Gain of Dams	49
Differences in Body Weight Gain of Dams, Mean	53
Reproduction Data Summary	54
Reproduction Data per Dam and Group	56
External Examination of Fetuses	60
Visceral Examination of Fetuses by Wilson Technique	60
Skeletal Examination of Fetuses (Abnormal Findings)	61
Skeletal Examination of Fetuses (Stage of Development)	
- Summary on a Fetus Basis	62
- Summary on a Litter Basis	64
Body Weights of Live Fetuses	66
Distribution within Uterus of Implantations, Live Fetuses and Resorptions (plan view)	70
Individual Contents of Uterus (plan view)	74
Mating/Necropsy Schedule and Individual Necropsy Findings	90

TABLES AND FIGURES (SUBGROUPS)

Food Consumption of Dams post coitum	- Figure	95
Food Consumption of Dams post coitum	- Tables	96
Differences in Food Consumption of Dams	- Mean	98
Body weights of Dams post coitum	- Figure	99
Body weights of Dams post coitum	- Tables	100
Differences on Body Weight Gain of Dams	- Mean	104
Individual Reproduction Data		105

CONTENTS REPORT PART I (cont'd)

		PAGE
Clinical Laboratory Investigations		107
Clinical Biochemistry Report		107
Clinical Biochemistry	- Summary	109
	- Individual	110
Organ Weights	- Summary	114
Organ/Body Weight Ratios	- Summary	115
Organ Weights	- Individual	116
Organ/Body Weight Ratios	- Individual	117
Mating/Blood Sampling and Individual Necropsy Findings		118
Macroscopical Findings		120
Pathology Report		124

ATTACHMENTS

Water Analyses - Bacteriological and Chemical Assays	163
Contaminant Analyses of Feed	166
Report of Determination of SXX 0665 TECHNICAL in Distilled Water with 0.5% Cremophor EL (BASF)	168
Historical Control Data and Spontaneous Abnormal Findings of Wistar Rats (SPF Quality) from 1986, 1987 and 1988	180

CONTENTS REPORT PART II

SKELETAL EXAMINATION OF FETUSES - INDIVIDUAL DATA	196

RCC PROJECT 236114
SXX 0665 TECHNICAL

QUALITY ASSURANCE UNIT

R C C REGISTRATION & CONSULTING COMPANY AG
CH 4452 ITINGEN/SWITZERLAND

S T A T E M E N T

PROJECT NUMBER: 236114

TEST ARTICLE: SXX 0665 TECHNICAL

STUDY DIRECTOR: H. Becker

TITLE: Embryotoxicity study (including teratogenicity) in the rat.

The conduct of this study was subjected to periodic inspections and the report audited by the Quality Assurance Unit. The dates are given below.

Dates of QAU Inspections / Audits	Dates of Reports to the Study Director and to Management
13.04.1989	14.04.1989
26.04.1989	26.04.1989
11.05.1989	11.05.1989
18.05.1989	18.05.1989
08.,13.-15.11.1991	15.11.1991

Manager, Quality Assurance Unit K. Schneider

i.A. B. Arbeit

Date: December 11, 1991

RCC PROJECT 236114
SXX 0665 TECHNICAL

PROJECT STAFF

STUDY DIRECTOR — H. Becker

.....
date: December 11, 1991

TECHNICAL COORDINATOR D. Frei

.....
date: April 9, 1990

CLINICAL BIOCHEMISTRY H. Luetkemeier

.....
date: May 22, 1991

ANALYTICAL CHEMISTRY K. Biedermann

.....
date: april 9, 1990

PATHOLOGY Dr. O. Vogel

.....
date: December 3, 1991

EDP AND STATISTICS Ch. Terrier

.....
date: April 9, 1990

MANAGING DIRECTOR Dr. K. Sachsse

.....
date: April 9, 1990

Confidential

Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

PREFACE

GENERAL

Title	Embryotoxicity study (including teratogenicity) with SXX 0665 TECHNICAL in the rat
Sponsor	BAYER AG Institut für Toxikologie Landwirtschaft Friedrich-Ebert-Str. 217 D-5600 Wuppertal 1 Federal Republic of Germany
Study Monitor	Dr. M. Renhof
Testing Facilities	RCC, Research & Consulting Company AG and RCC, Umweltchemie AG CH 4452 Itingen / Switzerland
Project Numbers	RCC : 236114 BAYER : T 1032691
Test Article	SXX 0665 TECHNICAL
Test System	Rat

PROJECT STAFF

Study Director	H. Becker
Technical Coordinator	D. Frei
Clinical Biochemistry	H. Luetkemeier
Analytical Chemistry	K. Biedermann
Pathology	Dr. O. Vogel
EDP and Statistics	Ch. Terrier

SCHEDULE

Delivery	April 14, 1989
Initiation (pairing)	April 24, 1989
Termination (last necropsy)	May 24, 1989

GUIDELINES

This study was conducted in compliance with:

Good Laboratory Practice (GLP) in Switzerland, Procedures and Principles. March 1986.

OECD Principles of Good Laboratory Practice, Paris, 1981.

U.S. Environmental Protection Agency - Pesticide Programs; Good Laboratory Practice Standards; Final Rule, U.S.A. Federal Register, Vol. 48, No. 230, November 29, 1983.

"Teratogenicity", OECD Guidelines for the Testing of Chemicals, Section 4, Health Effects, No. 414, May 12, 1981.

U.S. Environmental Protection Agency, Pesticide Assessment Guidelines - Subdivison F, Hazard Evaluation: Humans and Domestic Animals, Series 83-3 (Teratogenicity Study), revised edition, November 1984.

SUMMARY OF PROTOCOL AMENDMENTS

First Amendment

- Analyses of the test article/vehicle mixtures

Second Amendment

- Clinical Laboratory Investigations

SUMMARY (MAIN GROUPS)

The purpose of this study was to assess the effects of SXX 0665 TECHNICAL on embryonic and fetal development in pregnant Wistar/HAN rats.

Each group consisted of 25 mated female rats. SXX 0665 TECHNICAL was administered orally by gavage once daily from day 6 through to day 15 post coitum, at dose levels of:

Group 1: 0 mg/kg body weight/day (vehicle control)
Group 2: 10 mg/kg body weight/day
Group 3: 30 mg/kg body weight/day
Group 4: 100 mg/kg body weight/day

A standard dose volume of 10 ml/kg body weight with a daily adjustment to the actual body weight was used. Control animals were dosed with the vehicle alone (bi-distilled water with 0.5 % Cremophor EL).

Females were sacrificed on day 21 post coitum and the fetuses were removed by Caesarean section. The examination of the dams and fetuses was performed in accordance with international recommendations.

The following results were obtained:

GENERAL TOLERABILITY IN DAMS

- Oral administration of SXX 0665 TECHNICAL did not influence the viability or the behaviour and appearance of the animals in any dose group during the entire study. At necropsy, no treatment-related macroscopic changes were noted.

- Slightly reduced mean food consumption and marginally reduced mean body weight gain were noted at 100 mg/kg during the first half of the treatment period (days 6 to 11 post coitum).

REPRODUCTION PARAMETERS OF THE DAMS

- At 100 mg/kg, post-implantation loss was increased and consequently the number of live fetuses was reduced. Differences from the vehicle control group were statistically significant.

- All other differences from Control values were within the normal range of variation and considered not to be test article related effects.

FETAL PARAMETERS

- During external examination of the fetuses, three fetuses from three litters with different malformations were noted at 100 mg/kg. One fetus had palatoschisis, the second fetus had a shortened and constricted tail and the third fetus had palatoschisis, dysplastic lower jaw, arthrogryposis and most of the claws were missing.

- Fetal sex ratios and mean fetal body weights were similar in all groups.

SUMMARY (CONT'D MAIN GROUPS)

FETAL PARAMETERS (CONT'D)

- The visceral examination of fetuses by Wilson Technique as well as the skeletal examination of fetuses for abnormal findings gave no indication of test article-related effects.

- The examination of fetuses for the stage of skeletal development resulted in a dose-related statistically significant increase in the number of fetuses with supernumerary ribs at 10, 30 and 100 mg/kg.

- With the exception of this skeletal variant, all other differences from Control values at 10 and 30 mg/kg (although often statistically significant) were considered to be incidental as there was no trend.

- The fetuses at 100 mg/kg revealed a lower stage of ossification in several parts of the skeleton.

CONCLUSION (MAIN GROUPS)

SXX 0665 TECHNICAL was administered orally by gavage to mated Wistar/HAN rats at dosages of 0, 10, 30 or 100 mg/kg body weight/day from days 6 through to day 15 post coitum in order to assess the effects of the compound on embryonic and fetal development.

At 100 mg/kg, slightly reduced food consumption and marginally reduced body weight gain were noted.

Based on these results, the no-observable adverse effect level for the maternal organism was considered to be 30 mg/kg body weight/day.

In regard to embryonic/fetal development, an increased incidence of embryonic resorption was noted at 100 mg/kg and as a consequence, the number of live fetuses was reduced. The occurrence of three malformed fetuses at 100 mg/kg was possibly incidental; however, a slight effect on fetal development was indicated by a dose-related increased incidence of supernumerary rib(s) from 10 mg/kg upwards. In consideration of the supernumerary ribs, a no-observable adverse effect level for embryonic/fetal development was not attained.

Confidential
Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

SUMMARY (SUBGROUPS)

In addition, four subgroups each consisting of ten mated females, were similarly dosed from day 6 through to day 15 post coitum. On day 16 post coitum, blood samples were collected for determination of transaminase activity. After blood collection, the subgroup females were sacrificed, pregnancy status was recorded, livers were weighed and fixed in 4% formaldehyde solution for subsequent processing and histopathological examination.

The following results were obtained:

- As noted for the females of the main groups, slightly reduced food consumption and marginally reduced body weight gain were noted at 100 mg/kg during the first half of the dosing period (days 6 to 11 post coitum).
- No further reactions to treatment were observed and no abnormal findings were noted during necropsy.
- The evaluation of the reproduction parameters resulted in a slightly increased post-implantation loss at 100 mg/kg.
- No indication of treatment-related changes were noted in any dose group for plasma transaminase activity, (ASAT and ALAT) assessed at day 16 post coitum.
- The liver weight and the liver/body weight ratio were slightly increased at 10 and 30 mg/kg and significantly increased at 100 mg/kg.
- Treatment with SXX 0665 TECHNICAL was associated with hepatic lesions in rats of group 4 (100 mg/kg). These lesions were centrilobular hypertrophy and centrilobular/periportal fatty change. In addition, a treatment-related increase in severity of inflammatory cell foci was diagnosed in the rats of group 4 (100 mg/kg).

CONCLUSION (SUBGROUPS)

In the subgroup females of this study, the reaction to administration of the test article was similar to that noted in the females of the main groups.

Slightly reduced food consumption and body weight gain and slightly increased post-implantation loss were observed at 100 mg/kg.

From the additional parameters recorded (plasma transaminase activity, liver weights and liver pathology), an effect of treatment with SXX 0665 TECHNICAL was observed in the increased liver weights and histopathological changes observed in the liver at 100 mg/kg body weight/day.

Based on these results, the no-observable adverse effect level for the maternal organism was considered to be 30 mg/kg body weight/day.

OBJECTIVE

PURPOSE —

The purpose of this study was to assess the effects of SXX 0665 TECHNICAL on embryonic and fetal development when administered orally by gavage once daily to mated female rats from day 6 through to day 15 post coitum.

This study should provide a rational basis for risk assessment in man.

MATERIALS AND METHODS

Experimental Design

TEST SYSTEM

Species	Wistar/HAN Rats (WIST, Outbred, SPF Quality)
Rationale	Specified by the international guidelines as a recommended test system
Source	KFM, Kleintierfarm Madoerin AG CH 4414 Füllinsdorf / Switzerland
Acclimatization	10 days prior to pairing, under test conditions, after veterinary examination
Number of animals	140 mated females, 25 per main group, 10 per subgroup
Initial age (at pairing)	11 weeks, minimum
Initial body weight (day 0 post coitum)	183 - 231 grams
Identification (day 0 post coitum)	Individual cage/animal number tattooed on the pinnae

HUSBANDRY

Conditions

The animals were housed under standard laboratory conditions: air-conditioned with 10-15 air changes per hour; the environment monitored continuously with hourly recordings of temperature (range 22 +/- 3 degrees Centigrade) and humidity (range 40 - 70 %); 12 hours artificial fluorescent light/12 hours dark with background music (Schweizerischer Telefonrundspruch) played at a centrally defined low volume for at least 8 hours during the light period. The room number was documented in the raw data.

Accommodation

The animals were housed individually in Makrolon cages (type-3) with wire mesh tops and standardised granulated softwood bedding (Lignocel, Schill AG, CH 4132 Muttenz / Switzerland).

Diet

Pelleted standard Kliba 343 rat/mouse maintenance diet ("Kliba", Klingental-muehle AG, CH 4303 Kaiseraugst/Switzerland) was available ad libitum (Batch no. 42/89). Results of analyses for contaminants are attached (pp. 166, 167).

Water

Tap water was available ad libitum. Results of bacteriological, chemical and contaminant analyses are scheduled to be conducted at least once yearly by RCC (contaminant analyses only) and by the Official Chemist of the Kanton Basel-Landschaft (bacteriological and chemical analyses). Results are attached (pp. 163 - 165).

TEST ARTICLE

Identity	SXX 0665 TECHNICAL
Batch number	NLL 3622-2
Description	Light-beige powder
Purity	97.4% (according results of a re-analysis performed by the Sponsor dated May 16, 1989)
Storage	At room temperature, in the dark
Stability of the pure test article	Stable, at least until November 12, 1989 (according results of the re-analysis mentioned above)
Stability in the vehicle	At least two hours (see results of analysis, report pp. 168 - 179).
Safety precautions	Goggles and gloves

Confidential
Copyright by Bayer AG
the use, utilization or distribution
is only permitted with the consent
of Bayer AG.

PROCEDURES, OBSERVATIONS, DATA RECORDING AND COMPILATION

PROCEDURES

MATING

After acclimatization, the females were paired overnight with sexually mature males, in the ratio of 1 male: 1 female. The day on which spermatozoa were found in the vaginal smear or a vaginal plug was observed was designated day 0 post coitum.

ALLOCATION OF MATED FEMALES TO THE TEST GROUPS

Group	Maingroup Female Numbers	Subgroup* Female Numbers	Dose** mg/kg body weight
1	1 - 25	101 - 110	0 (vehicle control)
2	26 - 50	111 - 120	10
3	51 - 75	121 - 130	30
4	76 -100	131 - 140	100

* = Subgroup females for determination of transaminase activity, liver weights and liver histopathology.

** = Dose levels were chosen by the Sponsor.

METHOD OF ALLOCATION

Mated rats were assigned to the different groups using a computer-generated random algorithm.

ADMINISTRATION

The test article was administered orally, by gavage, once daily in the morning from day 6 through to day 15 post coitum. All groups received a dose volume of 10 ml/kg body weight, with a daily adjustment of the individual volume to the actual body weight. Control animals were similarly dosed with the vehicle alone.

RATIONALE

International guidelines recognize the efficacy of oral administration.

VEHICLE AND CONTROL ARTICLE

Bi-distilled water with 0.5% Cremophor EL (BASF) was used as the vehicle for the test article in the dose groups and was administered as the control article to the females of the Control group.

PREPARATION OF THE TEST ARTICLE/VEHICLE MIXTURES

The mixtures of the test article and vehicle were prepared daily before administration. SXX 0665 TECHNICAL was weighed into a glass beaker on a tared precision balance (Mettler PE 360) and the vehicle added (w/v). The mixtures were prepared using a homogenizer. During the daily administration period, homogeneity was maintained using a magnetic stirrer.

ANALYSES OF THE TEST ARTICLE/VEHICLE MIXTURES

Concentration, homogeneity and stability of the test article/vehicle mixtures were determined prior to the first test article administration. Samples were taken immediately after preparation and again 2 hours later. During the dosing period of this study, additional samples for confirmation of concentration and homogeneity were taken on one occasion. Analyses were performed by the RCC Analytical Chemistry Laboratory using a method supplied by the Sponsor. Results of the analyses are attached (pp. 168 - 179).

OBSERVATIONS

MORTALITY RATE

The animals were checked at least twice daily for any mortalities.

Any female sacrificed was subjected to macroscopic examination of the visceral organs, with emphasis on the uterus and its contents.

SIGNS AND/OR SYMPTOMS

The animals were observed at least twice daily for signs of reaction to treatment and/or symptoms of ill health.

DATA RECORDING

FOOD CONSUMPTION

Food consumption of maingroup females was recorded on days 6, 11, 16 and 21 post coitum and of subgroup females on days 6, 11 and 16 post coitum (see Data Compilation, p. 21 / Data Processing, p. 21).

BODY WEIGHTS

Body weights of maingroup females were recorded daily from day 0 until day 21 post coitum and of subgroup females daily from day 0 until day 16 post coitum (see Data Compilation, p. 21 / Data Processing, p. 21).

TERMINATION OF THE STUDY

On day 21 post coitum, the females were killed by CO_2 asphyxiation and the fetuses were removed by Caesarean section.

TERMINATION OF THE STUDY

The subgroup females were anesthetized by i. p. injection of pentobarbitone (Narcoren) and killed by exsanguisation on day 16 post coitum (after blood collection for clinical biochemistry). The pregnancy status of the females was recorded and the livers were weighed and fixed in 4% formaldehyde solution, processed and examined histopathologically (see pathology report, pp. 124-161).

All other tissues and organs were discarded.

The maingroup females were killed by CO_2 asphyxiation on day 21 post coitum and the fetuses removed by Caesarean section.

CAESAREAN SECTION AND POST MORTEM EXAMINATION

Post mortem examination, including gross macroscopic examination of all internal organs, with emphasis on the uterus, uterine contents, position of fetuses in the uterus and number of corpora lutea, was performed and the data recorded. The fetuses were removed from the uterus, sexed, weighed individually, examined for gross external abnormalities and allocated to one of the following procedures:

1) Wilson's slicing technique* for examination of the viscera and brain. One half of the live fetuses from each litter was fixed in a mixture of ethyl alcohol, formol and acetic acid. After examination the sections were preserved in a solution of ethyl alcohol and glycerine (one fetus per container). Descriptions of any abnormalities were recorded.

2) The remaining fetuses were placed in a solution of potassium hydroxide for clearing and stained with alizarin red S (modified technique**). The skeletons were examined and all abnormal findings and variations were recorded. The specimens were preserved individually in plastic bags.

The uteri (and contents) of all females with live fetuses were weighed at necropsy on day 21 post coitum to enable the calculation of the corrected body weight gain (see Data Processing).

If no implantation sites were evident, the uterus was placed in an aqueous solution of ammonium sulfide*** to accentuate possible hemorrhagic areas of implantation sites.

All tissues and organs except fetuses removed from animals killed at scheduled necropsy were discarded.

Fetuses with abnormalities were photographed.

---

* = Wilson, J.G. (1965) in: Teratology, Principles and Techniques, J.G. Wilson and J. Warkany, Eds., The University of Chicago Press, Chicago and London, pp. 265-277.
** = Dawson, A.B., (1926) Stain Techniques 1, pp. 123-124.
*** = Salewski, E., (1964) Arch. Exp. Path. Pharmak. 247, pp. 367-368.

RCC PROJECT 236114
SXX 0665 TECHNICAL

CLINICAL LABORATORY INVESTIGATIONS

GENERAL

Blood samples for clinical biochemistry were collected from 40 (10 females/group) nonfasted animals under light ether anesthesia. Blood samples were collected from each animal between the hours of 7.05 and 7.42 a.m. to reduce biological variation caused by circadian rhythms. Blood samples were drawn from the retroorbital plexus.

Blood sampling: at day 16 post coitum, 11/12 May, 1989.

CLINICAL BIOCHEMISTRY

The following anticoagulant were used during blood collection:
Lithium Heparin (140 U.S.P. Units).

The following commercial reference control was used to monitor the performance of the method:

Seronorm (normal range)
Pathonorm H (high range)
(Nyegaard & Co., Oslo/Norway)

The following methods were used to determine the values of the parameters listed:

Parameter	Method / Instrumentation	Unit of measure
Aspartate aminotransferase (ASAT/GOT)	Kinetic measurement of the rate of decrease in NADH (NADH/LDH coupled reaction). Method based on German Soc. for Clin. Chem. (DGKC) recommendations - Eris Selective Multi-Test Analyzer 6170 (Eppendorf/Olympus)	µkat/l (37°C)
Alanine aminotransferase (ALAT/GPT)	Kinetic measurement of the rate of decrease in NADH (NADH/LDH coupled reaction). Method based on German Soc. for Clin. Chem. (DGKC) recommendations - Eris Selective Multi-Test Analyzer 6170 (Eppendorf/Olympus)	µkat/l (37°C)

Confidential
Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

DATA COMPILATION

Food consumption, body weight, organ weight (subgroup females), macroscopic examination data (subgroup females), clinical laboratory investigation data (subgroup females) and Caesarean section data were recorded on-line and compiled by computer. Data of individual skeletal examination of fetuses were recorded on data sheets, transferred to and compiled by computer.

All other data were recorded on data sheets and compiled manually.

DATA PROCESSING

Mean daily food consumption was calculated using the following formula:

$$\frac{\text{Grams of food consumed per period}}{\text{Days per period}} = \text{Mean daily food consumption}$$

Body weight gains of maingroup females from days 0-6 p.c., 6-11 p.c., 11-16 p.c., 6-16 p.c., 16-21 p.c. and 6-21 p.c. were calculated.
Body weight gains of subgroup females were calculated from days 0-6 p.c., 6-11 p.c., 11-16 p.c. and 6-16 p.c..

Corrected body weight gain was calculated using the following formula:

Body weight on day 21 post coitum
- Body weight on day 6 post coitum
- Uterus weight at necropsy on day 21 post coitum

= Corrected body weight gain.

For evaluation of the reproduction data, the following formulae were used:

- pre-implantation loss (%):

$$\frac{\text{number of corpora lutea} - \text{number of implantations}}{\text{number of corpora lutea}} \times 100$$

- post-implantation loss (%):

$$\frac{\text{number of implantations} - \text{number of live fetuses}}{\text{number of implantations}} \times 100$$

- sex ratio of males/females (%):

$$\frac{\text{number of males/females}}{\text{number of live fetuses}} \times 100$$

Confidential
Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

DATA PROCESSING (CONT'D)

For the reproduction data, group mean values were calculated both on a per dam basis and on a percentage per group basis. Only dams with live fetuses on day 21 post coitum were included in the calculations.

Mean fetal weights were calculated from the individual fetal weights both on a per group and on a per litter basis.

Computer-generated values in the tables represent the rounded-off results of calculations which used the exact raw data values.

TERMINOLOGY USED IN THE ASSESSMENT OF THE DATA

Empty implantation site	- very early resorption or aborted implantation
Embryonic resorption	- amorphous mass being resorbed
Fetal resorption	- clearly defined fetal body being resorbed
Dead fetus	- appearance of live fetus but without respiration or movement
Live fetus	- breathing and/or moving fetus
Runt	- small fetus (<2.5 grams) (weight of a normally developed fetus, mean over several years: 4.5 - 4.9 grams)
Abnormal finding	- malformation and/or anomaly
Skeletal variant	- variations in the number of ribs and degree of ossification of phalangeal nuclei and/or sternebrae

ARCHIVING

The following data and specimens were archived by RCC, Research & Consulting Company AG, CH 4452 Itingen / Switzerland for at least 10 years:

protocol, report, duplicate of report, raw data of laboratory investigations, fetal sections, skeletal preparations of fetuses and test article reference sample.

RESULTS

SUMMARY OF PERFORMANCE OF MATED FEMALES (MAIN GROUPS)

Group Dose (mg/kg)	1 (0)	2 (10)	3 (30)	4 (100)
No. of mated females	25	25	25	25
Female nos.	1-25	26-50	51-75	76-100
No. of pregnant females	25	23(A)	24(B)	24(C)
No. of females with live fetuses at termination	25	23	24	24

(A) = Female nos. 30 and 45 were non-pregnant.

(B) = Female no. 69 was non-pregnant.

(C) = Female no. 90 was non-pregnant.

Only dams with live fetuses at termination on day 21 post coitum were included in the calculations of food consumption, body weight gain, corrected body weight gain and reproduction data.

MATERNAL DATA

SIGNS OF REACTION TO TREATMENT AND MORTALITIES:

No signs of reaction to the administration of the test article were observed and no deaths occurred during the course of this study.

FOOD CONSUMPTION (pp. 34 - 39):

In comparison with that of group 1 (vehicle control), mean food consumption was reduced in all dose groups during the recording period prior to test article administration. Therefore, the comparisons were performed within the groups. The results from these calculations showed a test article-related slight reduction only in group 4 (100 mg/kg), during the first half of the treatment period (days 6 to 11 post coitum).

All other differences noted were considered to be incidental and not related to test article administration.

MATERNAL DATA (CONT'D)

BODY WEIGHTS (pp. 40 - 53):

The mean body weight gain corresponded to the food consumption in all groups. Test article-related slight effects were only noted in group 4 (100 mg/kg) indicated by marginally reduced mean body weight gain also during the first half of the treatment period (days 6 to 11 post coitum).

No further changes in body weight gain in group 4 or in groups 2 (10 mg/kg) and 3 (30 mg/kg) were considered to be related to the administration of the test article.

NECROPSY FINDINGS (pp. 90 - 93):

No abnormal macroscopic findings were noted in any female of any dose group which were considered to be related to the administration of the test article.

REPRODUCTION DATA (pp. 54 - 59, 70 - 89):

There was a test article-related statistically significant increase in the post-implantation loss in the dams of group 4 (100 mg/kg), caused by an increased number of embryonic (statistically significant) and fetal resorptions.

The total loss amounted to 19.1 % in comparison with 3.9 % in group 1 (vehicle control). This significant post-implantation loss in group 4 also caused a statistically significant reduction of the number of fetuses per dam.

All the other differences between the reproduction parameters of group 1 (vehicle control) and groups 2 (10 mg/kg) and 3 (30 mg/kg), were within the normal range of variation and were considered to be incidental (including the statistically significantly increase of the post-implantation loss in group 3, see historical control data pp. 180 - 195).

FETAL DATA

EXTERNAL EXAMINATION (p. 60):

In group 4 (100 mg/kg), three fetuses were malformed. One fetus had palatoschisis, one fetus had a shortened and constricted tail and one fetus had palatoschisis, dysplastic lower jaw, arthrogryposis (both fore paws) and most of the claws of the fore and hind paws were missing. Further, there was a runt (body weight: 2.4 grams).

In both the Control group and group 3 (30 mg/kg), there was a runt (body weight: <2.5 grams).

No abnormal findings were noted in the fetuses of group 2 (10 mg/kg).

FETAL DATA (CONT'D)

SEX RATIOS (p. 55):

The sex ratio of fetuses in the vehicle control group was similar to those in the dose groups.

BODY WEIGHTS (Group mean p. 55; Litter mean pp. 66 - 69; Individual pp. 74 - 89):

Mean fetal body weights were similar in all groups. However, as a result of the increased post-implantation loss and consequent reduction in the number of fetuses per dam in group 4 (100 mg/kg), a slightly higher mean fetal body weight could have been expected because of the reduced intralitter competition in this group.

VISCERAL EXAMINATION BY WILSON TECHNIQUE (p. 60):

No abnormal findings were noted in the 139 fetuses of group 1 (vehicle control), the 123 fetuses of group 2 (10 mg/kg) or the 127 fetuses of group 3 (30 mg/kg).

In group 4 (100 mg/kg), one of the three malformed fetuses was examined by Wilson technique. In this fetus (no. 336), the palatoschisis was confirmed. No further abnormal findings were noted and no abnormal findings were noted in the other 111 fetuses of this group.

SKELETAL EXAMINATION (ABNORMAL FINDINGS, p. 61):

The type and frequency of abnormal findings gave no indication for test article specific effects. The following incidental abnormal findings were noted:

Group 1 (vehicle control):

8/156 fetuses (5.1 %) from 4/25 litters (16.0 %) had wavy ribs (one fetus with additionally incompletely ossified cranium).

Group 2 (10 mg/kg) and 3 (30 mg/kg):

No abnormal findings were noted in the 137 fetuses of 23 litters and in the 144 fetuses of 24 litters.

Group 4 (100 mg/kg):

3/125 fetuses (2.4 %) from 3/24 litters (12.5 %) had different findings. One fetus had one bipartite lumbar vertebral body, one fetus had two supernumerary ribs on the left and right side and in one fetus with abnormal findings noted during external examination (palatoschisis, slightly edematous, dysplastic lower jaw, arthrogryposis and missing claws) these findings were confirmed and additionally a curved radius of the right fore leg was ascertained.

FETAL EXAMINATION (CONT'D)

SKELETAL EXAMINATION (STAGE OF DEVELOPMENT, pp. 62 - 65):

A dose-related increase in the incidence of fetuses with supernumerary ribs was evident in groups 2 (10 mg/kg), 3 (30 mg/kg) and 4 (100 mg/kg). The differences in comparison with that of group 1 (vehicle control) attained statistical significance on a fetus basis as well as on a litter basis.

For group 2 (10 mg/kg), no other differences were considered to be test article-related. The few further significant differences were within the normal range of variation and considered to be incidental.

In groups 3 (30 mg/kg) and 4 (100 mg/kg), there were a few statistically significant differences in comparison with group 1 (vehicle control). In group 3, the significances in skeletal development were caused by a higher stage as well as by a lower stage of ossification. Because no trend was ascertained, these differences were considered to be incidental. For group 4, the significances were, with two exceptions, caused by a lower stage of ossification. These findings were considered to be a test article-related effect.

Confidential
Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

STATISTICAL ANALYSIS REPORT

SUMMARY

The food consumption values were significantly reduced in the group 3 animals between days 11 and 21 and in the group 4 animals between days 6 and 21 p.c.

On the basis of dams with live fetuses the group 3 animals showed significantly increased post-implantation loss and embryonic resorptions, the group 4 animals showed significantly increased post-implantation loss, embryonic and fetal resorptions and significantly reduced total fetuses in groups 3 and 4.

A lot of significant differences were noted in the skeletal findings between the control group and all treated groups based on individual fetuses and only some significant differences on a litter basis.

There was no further statistical evidence for differences between the treated groups and the control group.

STATISTICAL ANALYSIS REPORT

METHODS

The following statistical methods were used to analyze body weights, food consumption, reproduction and skeletal examination data:

Univariate one-way analysis of variance was used to assess the significance of intergroup differences.

If the variables could be assumed to follow a normal distribution, the Dunnett-test (many-one t-test), based on a pooled variance estimate, was applied for the comparison between the treated groups and the control group.

The Steel-test (many-one rank test) was applied when the data could not be assumed to follow a normal distribution.

Fisher's Exact test for 2x2 tables was applied if the variables could be dichotomized without loss of information.

Individual values, means, standard deviations and t-statistics were rounded off before printing.

References:

C. W. Dunnett, A Multiple Comparison Procedure for Comparing Several Treatments with a Control, J. Amer. Statist. Assoc. 50, 1096-121 (1955).

Rupert G. Miller, Simultaneous Statistical Inference, Springer Verlag, New York (1981).

Fisher, R.A. Statistical Methods for Research Workers, Oliver and Boyd, Edinburgh (1950).

STATISTICAL ANALYSIS REPORT

RESULTS

Only statistically significant results were reported. Unless stated otherwise, the test applied was the many-one t-test (Dunnett), based on a pooled estimate of the variance, and the significance level was 5%.

FOOD CONSUMPTION OF DAMS

The following significant differences between the control group and the treated groups were observed :

- The group 3 animals showed significantly reduced food consumption values between days 11 and 21 p.c..
- The group 4 animals showed significantly reduced food consumption values between days 6 and 21 p.c..

BODY WEIGHTS OF DAMS

There were noted no significant differences in the body weights between the control group and the treated groups.

CORRECTED BODY WEIGHT GAIN OF DAMS

There were noted no significant differences in the corrected body weight gain values between the control group and the treated groups.

REPRODUCTION DATA

According to Fisher's Exact test the following significant differences between the control group and the treated groups based on dams with live fetuses were observed :

- The number of post-implantation losses (in % of implantation sites) and the number of embryonic resorptions (in % of implantation sites) in animal groups 3 and 4 were significantly increased.
- The number of fetal resorptions (in % of implantation sites) was significantly increased in animal group 4.
- The number of total fetuses (in % of implantation sites) was significantly reduced in animal groups 3 and 4.

STATISTICAL ANALYSIS REPORT

RESULTS —

WEIGHTS OF LIVE FETUSES

There were noted no significant differences between the control group and the treated groups.

SKELETAL EXAMINATION

On individual fetuses basis there where noted a lot of significant differences between the control group and all treated groups.

On a litter basis there where noted only some significant differences between the control group and all treated groups.

The details will be shown in the skeletal examination summary report itself.

Confidential
Copy... the use, ... is only permitted with the consent of Bayer AG

SUMMARY OF PERFORMANCE OF MATED FEMALES OF THE SUBGROUPS FOR CLINICAL LABORATORY INVESTIGATIONS AND FOR DETERMINATION OF LIVER WEIGHTS AND LIVER HISTOPATHOLOGY

Group Dose (mg/kg)	1 (0)	2 (10)	3 (30)	4 (100)
No. of mated females	10	10	10	10
Female nos.	101-110	111-120	121-130	131-140
No. of females with live embryos at termination	9(A)	9(B)	10	10

(A) = Female no. 110 was non-pregnant.

(B) = Female no. 119 was non-pregnant.

Only dams with live embryos at termination on day 16 post coitum were included in the calculations of food consumption and body weight gain.

MATERNAL DATA

SIGNS OF REACTION TO TREATMENT AND MORTALITIES:

No deaths occurred during the course of this study and no signs of reaction to treatment were observed.

FOOD CONSUMPTION (pp. 95 - 98):

The mean food consumption corresponded to the mean food consumption of the main groups. Only in group 4 (100 mg/kg), the slight reduction during the first half of the treatment period (days 6 to 11 post coitum) was considered to be a test article-related effect.

BODY WEIGHTS (pp. 99 - 104):

As noted for the food consumption, only in group 4 (100 mg/kg) the body weight development was considered to be affected by treatment with the test article. During the first half of the treatment period (days 6 to 11 post coitum), the mean body weight gain was marginally reduced.

MATERNAL DATA (CONT'D)

NECROPSY FINDINGS (pp. 118, 119):

All females were necropsied on day 16 post coitum after blood collection. No abnormal findings were noted in any female of any group.

REPRODUCTION DATA (pp. 105, 106):

In comparison with that of the vehicle control group, the post-implantation loss of group 4 (100 mg/kg) was slightly increased. This finding was considered to be test article-related because at this dose level the post-implantation loss in the dams of the main group was also increased.

CLINICAL BIOCHEMISTRY (pp. 107 - 113):

The assessment of plasma transaminase activity (ASAT and ALAT) on day 16 post coitum indicated no treatment-related changes between control and treated female rats.

ORGAN WEIGHTS (LIVER ONLY) AND ORGAN BODY WEIGHT RATIOS (pp. 114 - 117):

The liver weights and the liver weight/body weight ratios were increased in all dose groups and attained statistical significance for both parameters in group 4. In comparison with the mean liver weight in the vehicle control, the differences amounted to 7.1 % in group 2 (10 mg/kg), to 1.1 % in group 3 (30 mg/kg) and to 14.4 % in group 4 (100 mg/kg).

PATHOLOGY DATA (LIVER ONLY) - (see Report pp. 124-161):

Inflammatory cell foci were noted in rats of all groups. In group 4 (100 mg/kg), the severity of these lesions was increased when compared with Control rats and rats of groups 2 (10 mg/kg) and 3 (30 mg/kg).

The following findings were only noted in rats of group 4 (100 mg/kg): centrilobular hypertrophy (6 rats), centrilobular fatty change (7 rats) and periportal fatty change (2 rats).

Confidential
Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

TABLES AND FIGURES (MAIN GROUPS)

DAYS P.C.

FOOD CONSUMPTION (G/ANIMAL/DAY)



	0-6	6-11	11-16	16-21 DAYS
GROUP 1 (0 MG/KG)				
MEAN	20.1	20.5	22.2	23.5
ST.DEV.	1.4	1.9	1.4	2.1
GROUP 2 (10 MG/KG)				
MEAN	19.2	20.1	21.4	22.9
ST.DEV.	1.3	1.6	1.8	1.3
GROUP 3 (30 MG/KG)				
MEAN	19.7	20.1	20.9	21.9
ST.DEV.	1.3	1.6	2.1	1.7
GROUP 4 (100 MG/KG)				
MEAN	19.5	18.7	20.7	21.7
ST.DEV.	1.8	1.9	1.7	2.4

DAYS P.C.

FOOD CONSUMPTION (G/ANIMAL/DAY)

GROUP 1 (0 MG/KG)

ANIMAL NUMBER	DAYS : 0-6	6-11	11-16	16-21
1	21	20	22	26
2	19	18	21	24
3	23	24	24	26
4	21	22	22	26
5	22	21	22	24
6	21	22	23	24
7	20	22	22	25
8	19	21	22	25
9	20	21	21	24
10	20	21	22	25
11	21	22	23	25
12	19	20	21	23
13	22	22	23	26
14	20	21	22	25
15	20	22	24	23
16	19	20	21	22
17	23	24	26	27
18	19	19	23	22
19	18	17	19	19
20	21	21	22	21
21	18	18	20	19
22	21	22	24	24
23	18	19	23	21
24	21	19	21	20
25	19	16	21	23

DAYS P.C.

FOOD CONSUMPTION (G/ANIMAL/DAY)

GROUP 2 (10 MG/KG)

ANIMAL NUMBER	DAYS : 0-6	6-11	11-16	16-21
26	20	20	22	24
27	20	21	23	25
28	18	18	18	23
29	20	21	20	23
30 *	19	19	14	16
31	19	19	20	22
32	22	23	23	23
33	19	20	20	22
34	18	19	19	22
35	18	21	21	24
36	19	21	21	24
37	17	17	18	22
38	20	22	22	24
39	19	20	21	22
40	19	20	21	23
41	17	17	18	20
42	20	20	23	24
43	21	21	23	23
44	21	21	22	24
45 *	18	17	14	12
46	21	22	25	25
47	19	20	23	21
48	20	21	23	22
49	19	19	23	23
50	20	19	23	23

(*) Animal not considered for evaluation

Confidential

Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG

DAYS P.C.

FOOD CONSUMPTION (G/ANIMAL/DAY)

GROUP 3 (30 MG/KG)

ANIMAL NUMBER	DAYS : 0-6	6-11	11-16	16-21
51	18	20	20	23
52	18	19	19	22
53	19	19	17	17
54	19	20	18	20
55	20	22	22	22
56	19	20	20	22
57	18	18	19	19
58	18	18	19	21
59	21	21	22	24
60	22	22	23	23
61	19	19	20	22
62	20	21	21	22
63	19	19	20	21
64	19	21	22	22
65	21	23	22	22
66	19	18	20	21
67	20	20	21	23
68	22	22	22	24
69 *	20	21	19	15
70	18	19	17	19
71	20	18	22	21
72	22	21	24	23
73	21	22	24	24
74	21	21	25	24
75	20	18	22	22

(*) Animal not considered for evaluation

SXX 0665 TECHNICAL 01-JUN-89

DAYS P.C.

FOOD CONSUMPTION (G/ANIMAL/DAY)

GROUP 4 (100 MG/KG)

ANIMAL NUMBER	DAYS : 0-6	6-11	11-16	16-21
76	21	21	24	26
77	19	18	22	26
78	20	21	21	23
79	18	18	21	20
80	19	18	20	23
81	19	17	17	19
82	19	18	20	17
83	22	19	21	24
84	17	17	18	19
85	23	24	23	23
86	21	22	20	24
87	21	20	22	23
88	18	18	21	21
89	18	20	21	22
90 *	16	16	14	15
91	20	17	20	22
92	17	17	19	18
93	18	17	21	19
94	17	16	19	21
95	23	18	20	24
96	19	17	21	18
97	20	17	21	22
98	19	19	22	22
99	22	21	25	23
100	21	19	21	23

(*) Animal not considered for evaluation

RCC PROJECT 236114
SXX 0665 TECHNICAL

DIFFERENCES IN FOOD CONSUMPTION OF DAMS, MEAN (G/ANIMAL/DAY) MAIN GROUPS

Group (mg/kg)	Days post coitum 0 - 6 g (%)	6 - 11 g (%)	11 - 16 g (%)
1 (0)	20.1	20.5 (+2.0)*	22.2 (+10.4)*
2 (10)	19.2 (-4.5)**	20.1 (+4.7)* (-2.0)**	21.4 (+11.5)* (-3.6)**
3 (30)	19.7 (-2.0)**	20.1 (+2.0)* (-2.0)**	20.9 (+6.1)* (-5.9)**
4 (100)	19.5 (-3.0)**	18.7 (-4.1)* (-8.8)**	20.7 (+6.2)* (-6.8)**

Group (mg/kg)	Days post coitum 6 - 16*** g (%)	16 - 21 g (%)
1 (0)	21.4 (+6.5)*	23.5 (+[illegible].9)*
2 (10)	20.8 (+8.3)* (-2.8)**	22.9 (+[illegible].3)* (-2.6)**
3 (30)	20.5 (+4.1)* (-4.2)**	21.9 (+[illegible].2)* (-6.8)**
4 (100)	19.7 (+1.0)* (-7.9)**	21.7 (+[illegible].3)* (-7.7)**

* = Percentages refer to the values of the pre-dosing period.

** = Percentages refer to the values of group 1.

*** = The calculations of food consumption and body weight gain during the treatment period started on day 6 post coitum (immediately prior to the first administration) and ended on day 16 post coitum (approximately 24 hours after the last administration).

BODY WEIGHTS OF DAMS P.C.



Confidential
Copyright by Bayer AG
the use, utilization or distribution is only permitted with the consent of Bayer AG.

GROUPS
1 : GROUP 1 (0 MG/KG)
2 : GROUP 2 (10 MG/KG)
3 : GROUP 3 (30 MG/KG)
4 : GROUP 4 (100 MG/KG)

BODY WEIGHTS OF DAMS P.C. (GRAM)

GROUP 1 (0 MG/KG)

ANIMAL NUMBER	DAYS P.C. : 0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
1	217	219	224	228	228	232	235	234	236	244	243	245	251	253	260	269
2	202	202	207	212	212	214	217	220	223	225	227	229	234	239	245	249
3	212	217	222	229	230	234	236	239	245	248	252	256	260	267	277	280
4	206	211	215	219	222	219	225	228	232	231	238	244	244	252	254	256
5	208	210	218	222	220	225	228	230	230	236	242	247	252	253	258	264
6	211	218	224	228	229	235	230	234	240	244	247	250	254	257	265	268
7	207	210	214	215	217	223	223	225	231	233	241	241	249	253	256	264
8	205	208	210	212	216	219	220	225	231	230	235	243	244	247	256	266
9	209	211	216	216	224	225	229	228	238	240	242	241	245	248	255	265
10	219	225	230	229	234	236	240	243	244	247	252	257	259	262	269	274
11	209	217	223	225	226	230	233	237	241	243	250	252	254	265	271	277
12	200	206	209	209	212	215	218	220	221	229	228	233	240	245	250	256
13	213	215	220	223	227	229	238	238	240	245	247	251	256	265	270	271
14	192	201	201	201	201	208	211	213	217	216	221	228	232	238	245	248
15	195	201	204	208	212	214	220	225	227	231	234	242	244	250	256	263
16	197	199	203	203	206	207	212	215	214	218	223	227	231	234	240	249
17	226	228	233	239	246	247	258	263	260	265	270	277	282	290	296	297
18	215	215	219	221	225	229	229	231	235	237	241	248	254	255	263	270
19	200	201	204	205	208	212	214	217	220	219	224	230	234	233	235	241
20	204	206	208	211	216	217	220	224	226	227	233	238	241	246	252	257
21	203	207	209	211	219	219	223	222	228	233	240	243	245	250	251	257
22	212	216	222	225	227	231	237	240	239	247	250	261	259	260	261	271
23	204	208	212	219	216	222	224	226	233	235	240	245	252	254	253	259
24	203	215	216	218	218	218	223	223	227	229	235	239	243	248	252	253
25	202	204	208	209	214	219	220	223	223	224	233	237	243	243	253	256
MEAN	207	211	215	217	220	223	227	229	232	235	240	244	248	252	258	263
ST.DEV.	7.8	7.6	8.6	9.5	9.8	9.7	10.5	10.7	10.2	11.3	11.0	11.3	11.0	12.1	12.6	12.0

BODY WEIGHTS OF DAMS P.C. (GRAM)

GROUP 1 (0 MG/KG)

ANIMAL NUMBER	DAYS P.C. : 16	17	18	19	20	21
1	281	295	303	319	332	346
2	256	268	277	285	299	309
3	294	306	321	333	346	360
4	265	276	292	305	316	326
5	276	288	300	315	333	335
6	278	290	299	313	325	333
7	275	280	293	308	315	331
8	271	282	292	306	317	331
9	269	283	293	301	317	331
10	284	294	305	313	321	332
11	281	295	307	309	318	338
12	265	277	292	298	311	321
13	283	293	307	312	322	343
14	253	265	279	292	301	313
15	272	281	295	303	317	328
16	254	265	280	287	301	313
17	310	320	332	339	358	376
18	274	284	299	304	320	327
19	250	255	263	272	286	287
20	266	271	291	296	317	318
21	272	275	290	296	312	311
22	289	292	307	313	327	335
23	278	278	295	306	316	318
24	269	267	282	290	299	309
25	265	272	288	298	308	317
MEAN	273	282	295	305	317	328
ST.DEV.	13.4	14.3	14.2	14.4	15.1	17.9

BODY WEIGHTS OF DAMS P.C. (GRAM)

GROUP 2 (10 MG/KG)

ANIMAL NUMBER	DAYS P.C. : 0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
26	215	216	220	229	227	233	233	237	238	242	243	249	252	260	266	272
27	217	218	220	226	229	230	234	235	236	249	249	250	256	262	265	274
28	203	203	208	211	210	216	216	222	221	221	226	229	234	236	241	245
29	190	198	205	202	207	210	212	216	218	220	224	225	226	228	231	233
30 *	193	196	203	206	204	210	209	211	214	213	218	215	210	211	211	209
31	197	198	205	206	210	214	215	219	224	225	226	234	234	236	245	250
32	198	200	208	211	215	217	219	225	227	229	233	234	240	245	249	257
33	205	211	214	216	223	226	223	233	236	236	241	247	245	249	252	262
34	203	205	212	216	215	219	219	223	223	230	231	235	239	242	246	250
35	203	205	209	210	213	215	216	223	230	226	231	239	242	247	249	260
36	194	197	205	207	207	214	212	219	223	222	225	230	238	239	244	250
37	190	191	195	201	200	205	206	210	208	212	215	218	224	229	235	237
38	209	209	215	217	221	223	226	230	234	237	240	247	256	256	262	269
39	203	210	214	216	217	222	223	227	226	230	235	238	244	253	256	261
40	214	216	219	221	226	231	237	238	242	244	250	252	256	264	267	275
41	192	193	197	201	201	208	209	211	213	216	221	221	226	229	238	243
42	211	212	217	222	221	228	231	234	231	235	237	239	246	257	259	268
43	196	201	206	205	210	211	214	216	215	218	221	230	229	235	242	245
44	209	212	212	222	221	227	228	234	236	239	244	253	248	261	265	274
45 *	204	204	210	208	213	216	217	218	220	219	223	219	216	210	211	214
46	230	229	232	237	239	243	246	249	251	255	262	270	271	278	282	285
47	191	195	197	203	208	205	208	212	215	219	223	236	239	244	247	257
48	216	218	223	228	232	231	239	236	239	246	246	257	258	265	272	271
49	196	201	207	209	211	212	216	219	221	225	227	235	239	246	246	252
50	201	203	209	213	214	222	223	226	228	228	229	240	239	245	246	256
MEAN	204	206	211	214	216	220	222	226	228	231	234	239	243	248	252	259
ST.DEV.	10.3	9.5	8.8	9.9	9.9	9.9	10.8	10.1	10.5	11.4	11.5	12.3	11.7	13.2	12.8	13.5

(*) Female not considered for evaluation

Confidential

Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

BODY WEIGHTS OF DAMS P.C. (GRAM)

GROUP 2 (10 MG/KG)

ANIMAL NUMBER	DAYS P.C. : 16	17	18	19	20	21
26	282	295	315	324	338	346
27	284	299	305	319	331	345
28	253	259	272	279	290	305
29	237	242	246	249	245	258
30 *	212	211	213	216	213	220
31	260	262	275	285	292	309
32	264	271	280	286	298	308
33	267	283	292	303	319	326
34	260	266	278	287	297	306
35	266	275	285	297	312	325
36	265	274	285	298	309	319
37	247	256	269	282	292	307
38	278	291	305	320	332	346
39	273	284	294	307	320	336
40	281	292	308	318	332	339
41	247	256	266	275	286	302
42	277	281	297	304	314	331
43	259	264	275	282	295	312
44	285	296	313	321	341	350
45 *	212	211	215	214	216	216
46	297	304	319	327	346	357
47	266	277	288	294	315	319
48	288	297	312	321	340	337
49	266	274	285	297	308	319
50	266	273	289	294	306	317
MEAN	268	277	289	299	311	323
ST.DEV.	14.6	16.3	18.3	19.4	23.3	21.6

(*) Female not considered for evaluation

BODY WEIGHTS OF DAMS P.C. (GRAM)

GROUP 3 (30 MG/KG)

ANIMAL NUMBER	DAYS P.C. : 0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
51	204	207	208	212	213	219	219	220	223	228	229	237	238	241	252	256
52	217	218	223	224	228	229	230	234	237	238	239	243	248	253	257	266
53	188	194	202	202	201	205	204	209	213	214	218	219	226	226	229	236
54	198	202	207	210	203	208	209	218	220	221	227	224	233	232	236	244
55	213	215	219	226	228	229	231	233	237	242	246	250	252	260	268	278
56	191	196	202	208	207	210	214	218	216	222	225	228	235	237	240	247
57	191	195	201	202	204	204	205	209	212	215	217	217	223	232	233	247
58	199	202	202	208	212	212	215	218	220	221	222	227	231	232	238	244
59	213	216	220	222	227	229	237	238	240	243	245	253	255	261	263	273
60	218	223	228	227	231	235	240	244	241	244	249	256	254	262	267	268
61	191	196	197	199	200	206	209	212	209	212	214	219	223	227	233	238
62	205	213	218	221	223	221	226	229	231	234	240	243	246	248	256	265
63	196	200	205	206	209	212	215	218	216	222	222	229	232	235	239	245
64	191	195	198	199	203	206	215	216	216	219	221	229	230	235	242	245
65	217	222	223	227	228	235	235	244	239	244	251	259	259	266	268	276
66	196	201	204	205	208	212	217	218	218	221	223	230	235	240	243	248
67	206	208	213	217	216	218	226	229	229	234	236	240	244	249	254	260
68	213	220	224	226	226	232	237	240	243	248	249	253	254	260	265	278
69 *	209	211	214	217	222	226	231	232	235	236	236	242	235	241	244	246
70	202	203	206	210	214	220	219	224	230	228	234	239	241	248	247	255
71	210	212	216	224	221	226	227	227	227	231	234	238	245	249	255	257
72	220	221	229	232	237	240	241	244	243	251	259	259	262	271	275	273
73	231	231	240	243	250	250	256	257	263	264	267	273	279	283	290	293
74	212	213	220	221	229	232	235	233	242	247	245	255	260	267	270	274
75	207	226	215	218	222	224	222	227	227	231	231	237	241	243	243	251
MEAN	205	210	213	216	218	221	224	227	229	232	235	240	244	248	253	259
ST.DEV.	11.3	11.1	11.3	11.5	12.9	12.5	13.0	12.6	13.2	13.5	14.1	14.9	14.0	15.3	15.7	15.1

(*) Female not considered for evaluation

SXX 0665 TECHNICAL

01-JUN-89

BODY WEIGHTS OF DAMS P.C. (GRAM)

GROUP 3 (30 MG/KG)

ANIMAL NUMBER	DAYS P.C. : 16	17	18	19	20	21
51	263	271	281	296	303	319
52	271	276	293	303	320	330
53	238	247	258	268	274	288
54	249	261	273	286	293	304
55	283	299	314	324	341	347
56	254	263	275	298	296	311
57	248	260	275	282	296	306
58	254	261	277	286	298	311
59	281	293	307	321	330	345
60	281	288	300	311	317	334
61	249	255	268	274	283	297
62	272	280	300	305	318	333
63	252	259	271	279	289	307
64	259	265	278	284	295	310
65	287	295	312	316	327	345
66	259	264	278	288	298	308
67	269	276	288	300	311	326
68	288	297	305	315	330	350
69 *	244	240	239	235	238	232
70	262	267	284	288	308	308
71	262	275	290	299	316	327
72	284	291	297	308	317	328
73	302	309	320	329	343	349
74	294	300	315	328	345	350
75	258	268	274	291	302	315
MEAN	267	276	289	299	310	323
ST.DEV.	16.8	16.9	17.2	17.4	19.2	18.4

(*) Female not considered for evaluation

BODY WEIGHTS OF DAMS P.C. (GRAM)

GROUP 4 (100 MG/KG)

ANIMAL NUMBER	DAYS P.C. : 0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
76	217	226	222	232	231	232	237	233	236	237	244	246	250	251	252	261
77	207	211	212	218	217	223	223	224	222	229	230	238	240	249	252	255
78	209	212	216	215	220	224	227	230	233	236	237	246	247	250	258	266
79	201	204	207	210	209	214	216	215	219	222	225	231	235	241	245	257
80	215	217	221	224	227	229	232	233	234	235	240	247	252	255	259	266
81	202	203	208	210	213	215	219	217	217	222	224	227	229	236	240	244
82	203	204	213	212	212	217	218	220	221	221	225	227	234	235	242	251
83	198	202	209	211	214	214	216	219	220	214	224	223	231	233	240	249
84	192	196	200	202	205	206	205	205	208	213	212	213	218	220	220	221
85	220	225	233	237	239	244	246	252	254	255	260	262	269	273	279	283
86	216	219	231	231	233	238	242	246	246	248	255	257	261	265	268	275
87	210	213	214	215	220	222	228	234	235	237	241	245	247	253	262	263
88	210	219	219	221	228	228	229	228	236	236	239	247	249	257	263	271
89	195	200	200	202	206	208	210	209	211	213	217	225	225	225	233	238
90 *	191	195	197	202	204	205	211	212	214	215	213	214	210	209	213	214
91	221	225	226	231	233	235	238	239	235	235	239	250	250	257	266	270
92	192	194	197	200	202	204	208	210	209	212	212	218	219	224	232	238
93	212	216	219	222	223	228	231	232	233	235	238	244	253	255	262	273
94	198	205	203	208	207	211	214	220	217	224	227	235	237	241	249	250
95	210	215	221	222	227	229	232	232	233	234	238	248	251	253	261	262
96	195	196	200	202	205	209	210	214	213	219	220	232	230	233	239	239
97	218	219	226	229	232	234	235	235	234	237	246	248	249	258	263	266
98	211	216	218	221	223	225	228	230	230	232	235	242	245	249	254	258
99	215	217	222	228	231	232	236	239	240	245	246	258	260	266	269	274
100	214	217	226	227	233	234	238	241	242	241	248	253	257	257	261	266
MEAN	208	211	215	218	220	223	226	227	228	231	234	240	243	247	253	258
ST.DEV.	9.1	9.6	10.3	10.8	11.1	11.1	11.6	12.2	12.3	11.7	12.8	13.1	13.4	14.0	14.1	14.7

(*) Female not considered for evaluation

Confidential

Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

BODY WEIGHTS OF DAMS P.C. (GRAM)

GROUP 4 (100 MG/KG)

ANIMAL NUMBER	DAYS P.C. : 16	17	18	19	20	21
76	270	278	291	294	302	310
77	270	285	300	313	333	343
78	273	282	300	308	321	334
79	261	266	276	285	292	301
80	276	283	301	311	327	339
81	257	261	276	291	299	309
82	256	262	273	279	287	298
83	251	259	274	279	293	309
84	226	225	230	234	235	236
85	292	300	302	315	318	329
86	281	292	306	317	329	345
87	276	282	296	305	320	331
88	281	285	300	306	317	334
89	243	249	255	264	269	285
90 *	215	210	215	214	211	214
91	278	285	298	305	311	324
92	247	252	263	271	278	285
93	283	286	305	310	330	334
94	259	272	276	294	306	318
95	277	293	301	318	332	349
96	247	253	259	268	276	286
97	277	286	291	301	308	317
98	271	271	284	292	305	306
99	290	289	308	320	336	347
100	275	280	289	304	317	323
MEAN	267	274	286	295	306	316
ST.DEV.	16.2	17.5	19.6	20.9	24.3	26.1

(*) Female not considered for evaluation

Confidential

Copyright by Bayer AG
the use, utilisation, [illegible] is only permitted with the consent of Bayer AG.

CORRECTED BODY WEIGHT GAIN GROUP 1 (0 MG/KG)

FEMALE	WEIGHT ON DAY 6 P.C.	WEIGHT ON DAY OF SECTION	WEIGHT OF UTERUS	CORRECTED WEIGHT GAIN GRAM<1>	CORRECTED WEIGHT GAIN PERCENT<2>
1	235	346	88.5	22.5	9.6
2	217	309	62.1	29.9	13.8
3	236	360	90.2	33.8	14.3
4	225	326	82.6	18.4	8.2
5	228	335	92.2	14.8	6.5
6	230	333	85.3	17.7	7.7
7	223	331	76.3	31.7	14.2
8	220	331	72.7	38.3	17.4
9	229	331	71.1	30.9	13.5
10	240	332	70.7	21.3	8.9
11	233	338	67.7	37.3	16.0
12	218	321	79.8	23.2	10.7
13	238	343	68.3	36.7	15.4
14	211	313	78.1	23.9	11.3
15	220	328	78.5	29.5	13.4
16	212	313	84.7	16.3	7.7
17	258	376	82.6	35.4	13.7
18	229	327	74.1	23.9	10.4
19	214	287	57.5	15.5	7.3
20	220	318	84.3	13.7	6.2
21	223	311	81.3	6.7	3.0
22	237	335	74.1	23.9	10.1
23	224	318	79.8	14.3	6.4
24	223	309	69.2	16.8	7.5
25	220	317	72.5	24.5	11.1
		N	25	25	25
		MEAN	77.0	24.0	10.6
		ST.DEV.	8.6	8.6	3.7

<EX> : Animal Excluded from Evaluation
<1> : (Weight on Day of Section) - (Weight on Day 6 P.C.) - (Weight Uterus)
<2> : Corrected Weight Gain in Percent of Weight on Day 6 P.C.

CORRECTED BODY WEIGHT GAIN
GROUP 2 (10 MG/KG)

FEMALE	WEIGHT ON DAY 6 P.C.	WEIGHT ON DAY OF SECTION	WEIGHT OF UTERUS	CORRECTED WEIGHT GAIN GRAM<1>	CORRECTED WEIGHT GAIN PERCENT<2>
26	233	346	93.0	20.0	8.6
27	234	343	85.9	25.1	10.7
28	216	305	10.5	78.5	36.3
29	212	258	57.6	-11.6	-5.5
30 <EX>					
31	215	309	66.9	27.1	12.6
32	219	308	63.0	26.0	11.9
33	223	326	79.9	23.1	10.4
34	219	306	71.6	15.4	7.0
35	216	325	79.9	29.1	13.5
36	212	319	77.5	29.5	13.9
37	206	307	79.4	21.6	10.5
38	226	346	89.7	30.3	13.4
39	223	336	84.5	28.5	12.8
40	237	339	86.5	15.5	6.5
41	209	302	74.7	18.3	8.7
42	231	331	67.5	32.5	14.1
43	214	312	74.1	23.9	11.2
44	228	350	100.4	21.6	9.5
45 <EX>					
46	246	357	79.5	31.5	12.8
47	208	319	86.0	25.0	12.0
48	239	337	85.0	13.0	5.5
49	216	319	72.7	30.3	14.0
50	223	317	62.2	31.8	14.3
		N	23	23	23
		MEAN	75.1	25.5	11.5
		ST.DEV.	17.5	14.9	6.9

<EX> : Animal Excluded from Evaluation
<1> : (Weight on Day of Section) - (Weight on Day 6 P.C.) - (Weight Uterus)
<2> : Corrected Weight Gain in Percent of Weight on Day 6 P.C.

CORRECTED BODY WEIGHT GAIN
GROUP 3 (30 MG/KG)

FEMALE	WEIGHT ON DAY 6 P.C.	WEIGHT ON DAY OF SECTION	WEIGHT OF UTERUS	CORRECTED WEIGHT GAIN GRAM<1>	CORRECTED WEIGHT GAIN PERCENT<2>
51	219	319	69.7	30.3	13.8
52	230	330	74.9	25.1	10.9
53	204	288	72.3	11.7	5.7
54	209	304	71.5	23.5	11.2
55	231	347	95.7	20.3	8.8
56	214	311	75.3	21.7	10.1
57	205	306	85.6	15.4	7.5
58	215	311	71.3	24.7	11.5
59	237	345	96.1	11.9	5.0
60	240	334	70.5	23.5	9.8
61	209	297	63.1	24.9	11.9
62	226	333	92.1	14.9	6.6
63	215	307	65.1	26.9	12.5
64	215	310	71.0	24.0	11.2
65	235	345	88.2	21.8	9.3
66	217	308	69.4	21.6	10.0
67	226	326	74.8	25.2	11.1
68	237	350	90.8	22.2	9.4
69 <EX>					
70	219	308	76.4	12.6	5.8
71	227	327	90.9	9.1	4.0
72	241	328	65.7	21.3	8.8
73	256	349	66.4	26.6	10.4
74	235	350	89.1	25.9	11.0
75	222	315	74.7	18.3	8.2
		N	24	24	24
		MEAN	77.5	21.0	9.4
		ST.DEV.	10.5	5.6	2.5

<EX> : Animal Excluded from Evaluation
<1> : (Weight on Day of Section) - (Weight on Day 6 P.C.) - (Weight Uterus)
<2> : Corrected Weight Gain in Percent of Weight on Day 6 P.C.

CORRECTED BODY WEIGHT GAIN
GROUP 4 (100 MG/KG)

FEMALE	WEIGHT ON DAY 6 P.C.	WEIGHT ON DAY OF SECTION	WEIGHT OF UTERUS	CORRECTED WEIGHT GAIN GRAM<1>	CORRECTED WEIGHT GAIN PERCENT<2>
76	237	310	41.1	31.9	13.4
77	223	343	85.2	34.8	15.6
78	227	334	81.2	25.8	11.4
79	216	301	72.2	12.8	5.9
80	232	339	87.3	19.7	8.5
81	219	309	85.3	4.7	2.1
82	218	298	71.4	8.6	3.9
83	216	309	69.5	23.5	10.9
84	205	236	11.5	19.5	9.5
85	246	329	62.2	20.8	8.5
86	242	345	80.0	23.0	9.5
87	228	331	78.9	24.1	10.6
88	229	334	84.9	20.1	8.8
89	210	285	39.2	35.8	17.0
90 <EX>					
91	238	324	62.4	23.6	9.9
92	208	285	65.3	11.7	5.6
93	231	334	99.0	4.0	1.7
94	214	318	77.5	26.5	12.4
95	232	349	88.4	28.6	12.3
96	210	286	47.2	28.8	13.7
97	235	317	57.2	24.8	10.6
98	228	306	63.1	14.9	6.5
99	236	347	88.2	22.8	9.7
100	238	323	66.3	18.7	7.9
		N	24	24	24
		MEAN	69.4	21.2	9.4
		ST.DEV.	19.7	8.5	3.8

<EX> : Animal Excluded from Evaluation
<1> : (Weight on Day of Section) - (Weight on Day 6 P.C.) - (Weight Uterus)
<2> : Corrected Weight Gain in Percent of Weight on Day 6 P.C.

Confidential
Copyright by Bayer AG
The use, publication or distribution
is only permitted with the consent
of Bayer AG.

DIFFERENCES IN BODY WEIGHT GAIN OF DAMS, MEAN (MAIN GROUPS)

Group (mg/kg)	Days post coitum 0 - 6 g (%)	6 - 11 g (%)	11 - 16 g (%)	6 - 16* g (%)
1 (0)	20 (+9.7)	17 (+7.5)	29 (+11.9)	46 (+20.3)
2 (10)	18 (+8.8)	17 (+7.7)	29 (+12.1)	46 (+20.7)
3 (30)	19 (+9.3)	16 (+7.1)	27 (+11.3)	43 (+19.2)
4 (100)	18 (+8.7)	14 (+6.2)	27 (+11.3)	41 (+18.1)

* = The calculations of food consumption and body weight gain during the treatment period started on day 6 post coitum (immediately prior to the first administration) and ended on day 16 post coitum (approximately 24 hours after the last administration).

Group (mg/kg)	Days post coitum 16 - 21 g (%)	6 - 21 g (%)	Corrected body weight gain % (see pp. 49 - 52)
1 (0)	55 (+20.1)	101 (+44.5)	+10.6
2 (10)	55 (+20.5)	101 (+45.5)	+11.5
3 (30)	56 (+21.0)	99 (+44.2)	+ 9.4
4 (100)	49 (+18.4)	90 (+39.8)	+ 9.4

REPRODUCTION DATA SUMMARY

	GROUP 1 0 MG/KG	GROUP 2 10 MG/KG	GROUP 3 30 MG/KG	GROUP 4 100 MG/KG
NUMBER OF DAMS	25	23	24	24
CORPORA LUTEA				
MEAN (+)	347	313	321	337
ST.DEV.	13.9	13.6	13.4	14.0
	2.0	1.5	1.7	2.0
PRE-IMPLANTATION LOSS				
% OF CORP. LUTEA (#)	40	36	27	44
MEAN (+)	11.5	11.5	8.4	13.1
ST.DEV.	1.6	1.6	1.1	1.8
NUMBER OF DAMS AFFECTED	1.5	1.7	1.0	2.2
	19	16	15	18
IMPLANTATION SITES				
% OF CORP. LUTEA (#)	307	277	294	293
MEAN (+)	88.5	88.5	91.6	86.9
ST.DEV.	12.3	12.0	12.3	12.2
	1.5	2.8	1.6	2.6
POST-IMPLANTATION LOSS				
% OF IMPL. SITES (#)	12	17	23	56
MEAN (+)	3.9	6.1	7.8 #	19.1 ##
ST.DEV.	0.5	0.7	1.0	2.3
NUMBER OF DAMS AFFECTED	0.8	0.9	0.9	1.9
	8	12	15	17
IMPLANTATION SITE SCARS	0	0	0	0
EMBRYONIC DEATHS : TOTAL	12	17	23	56
EMBRYONIC RESORPTIONS				
% OF IMPL. SITES (#)	11	17	22	43
MEAN (+)	3.6	6.1	7.5 #	14.7 ##
ST.DEV.	0.4	0.7	0.9	1.8
NUMBER OF DAMS AFFECTED	0.8	0.9	0.8	1.7
	8	12	15	16
FETAL RESORPTIONS				
% OF IMPL. SITES (#)	1	0	1	13
MEAN (+)	0.3		0.3	4.4 ##
ST.DEV.	0.0		0.0	0.5
NUMBER OF DAMS AFFECTED	0.2		0.2	0.9
	1		1	8
FETUSES				
TOTAL FETUSES				
% OF IMPL. SITES (#)	295	260	271	237
MEAN (+)	96.1	93.9	92.2 #	80.9 ##
ST.DEV.	11.8	11.3	11.3	9.9
	1.7	2.8	1.6	3.2
LIVE FETUSES	295	260	271	237
DEAD FETUSES	0	0	0	0
ABNORMAL FETUSES				
% OF FETUSES (#)	1	0	1	3
MEAN (+)	0.3		0.4	1.3
ST.DEV.	0.0		0.0	0.1
NUMBER OF DAMS AFFECTED	0.2		0.2	0.3
	1		1	3
ABNORMAL LIVE FETUSES AT EXTERNAL EXAMINATION	1	0	1	3
ABNORMAL DEAD FETUSES AT EXTERNAL EXAMINATION	0	0	0	0

*/** : Dunnett-Test based on pooled variance significant at level 5% (*) or 1% (**)
#/## : Fisher's Exact Test significant at level 5% (#) or 1% (##)
+ : Steel Test significant at level 5%

Confidential
Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG

REPRODUCTION DATA SUMMARY

	GROUP 1 0 MG/KG	GROUP 2 10 MG/KG	GROUP 3 30 MG/KG	GROUP 4 100 MG/KG
NUMBER OF DAMS	25	23	24	24
SEX OF FETUSES				
TOTAL MALES	145	138	128	106
% OF FETUSES (#)	49.2	53.1	47.2	44.7
MEAN	5.8	6.0	5.3	4.4
ST.DEV.	2.0	2.2	1.4	2.2
TOTAL FEMALES	150	122	143	131
% OF FETUSES (#)	50.8	46.9	52.8	55.3
MEAN	6.0	5.3	6.0	5.5
ST.DEV.	2.1	2.1	1.5	1.9
LIVE MALES	145	138	128	106
LIVE FEMALES	150	122	143	131
WEIGHTS OF LIVE FETUSES (LITTER BASIS)				
TOTAL FETUSES				
N (LITTERS)	25	23	24	24
MEAN (*)	4.8	4.9	4.9	4.7
ST.DEV.	0.3	0.3	0.3	0.4
MALES				
N (LITTERS)	25	23	24	22
MEAN (*)	4.9	5.0	5.1	4.8
ST.DEV.	0.3	0.3	0.3	0.5
FEMALES				
N (LITTERS)	25	22	24	24
MEAN (*)	4.7	4.7	4.8	4.7
ST.DEV.	0.3	0.3	0.2	0.3
WEIGHTS OF LIVE FETUSES (INDIVIDUAL BASIS)				
TOTAL FETUSES				
N (FETUSES)	295	260	271	237
MEAN	4.8	4.9	4.9	4.7
ST.DEV.	0.4	0.4	0.4	0.5
MALES				
N (FETUSES)	145	138	128	106
MEAN	4.9	5.0	5.0	4.8
ST.DEV.	0.4	0.4	0.5	0.6
FEMALES				
N (FETUSES)	150	122	143	131
MEAN	4.7	4.8	4.8	4.7
ST.DEV.	0.4	0.4	0.4	0.5

*/** : Dunnett-Test based on pooled variance significant at level 5% (*) or 1% (**)
#/## : Fisher's Exact Test significant at level 5% (#) or 1% (##)
+ : Steel Test significant at level 5%

REPRODUCTION DATA
GROUP 1 (0 MG/KG)

FEMALE	CORP. LUTEA	IMPL.	-EMBRYONIC DEATHS-- TOTAL	EMBR. STAGE	FETAL STAGE	FETUSES TOTAL	LIVE MALE	LIVE FEM.	DEAD MALE	DEAD FEM.	MALF. MALE	MALF. FEM.
1	14	13	0	0	0	13	4	9	0	0	0	0
2	12	9	0	0	0	9	5	4	0	0	0	0
3	17	15	0	0	0	15	7	8	0	0	0	0
4	15	13	0	0	0	13	10	3	0	0	0	0
5	15	14	0	0	0	14	7	7	0	0	0	0
6	15	13	0	0	0	13	9	4	0	0	0	0
7	13	12	0	0	0	12	3	9	0	0	0	0
8	11	11	0	0	0	11	6	5	0	0	0	0
9	14	11	0	0	0	11	7	4	0	0	0	0
10	14	12	1	1	0	11	5	6	0	0	0	0
11	14	11	1	1	0	10	4	6	0	0	0	0
12	14	13	0	0	0	13	9	4	0	0	0	0
13	20	13	3	3	0	10	4	6	0	0	0	1
14	15	13	1	1	0	12	6	6	0	0	0	0
15	13	13	2	2	0	11	6	5	0	0	0	0
16	13	13	0	0	0	13	8	5	0	0	0	0
17	15	14	0	0	0	14	4	10	0	0	0	0
18	14	13	2	1	1	11	4	7	0	0	0	0
19	12	9	1	1	0	8	5	3	0	0	0	0
20	13	13	0	0	0	13	3	10	0	0	0	0
21	15	13	0	0	0	13	7	6	0	0	0	0
22	15	13	1	1	0	12	3	9	0	0	0	0
23	12	12	0	0	0	12	6	6	0	0	0	0
24	11	10	0	0	0	10	6	4	0	0	0	0
25	11	11	0	0	0	11	7	4	0	0	0	0
TOTAL	347	307	12	11	1	295	145	150	0	0	0	1
MEAN	13.9	12.3	0.5	0.4	0.0	11.8	5.8	6.0				0.0
ST.DEV.	2.0	1.5	0.8	0.8	0.2	1.7	2.0	2.1				0.2

RCC PROJECT 236114
SXX 0665 TECHNICAL

CAE-DAM - 2
25-APR-91

Confidential

Copyright by Bayer AG
the use, utilization or distribution
is only permitted with the consent
of Bayer AG

REPRODUCTION DATA
GROUP 2 (10 MG/KG)

FEMALE	CORP. LUTEA	IMPL.	-EMBRYONIC DEATHS-- TOTAL	EMBR. STAGE	FETAL STAGE	FETUSES TOTAL	LIVE MALE	LIVE FEM.	DEAD MALE	DEAD FEM.	MALF. MALE	MALF. FEM.
26	14	14	1	1	0	13	7	6	0	0	0	0
27	15	13	0	0	0	13	6	7	0	0	0	0
28	8	1	0	0	0	1	1	0	0	0	0	0
29	12	10	2	2	0	8	5	3	0	0	0	0
30 <NP>												
31	14	13	2	2	0	11	5	6	0	0	0	0
32	14	10	1	1	0	9	2	7	0	0	0	0
33	16	13	1	1	0	12	6	6	0	0	0	0
34	15	12	1	1	0	11	7	4	0	0	0	0
35	13	13	1	1	0	12	2	10	0	0	0	0
36	13	12	0	0	0	12	5	7	0	0	0	0
37	14	12	0	0	0	12	6	6	0	0	0	0
38	14	13	0	0	0	13	7	6	0	0	0	0
39	14	13	0	0	0	13	6	7	0	0	0	0
40	13	13	0	0	0	13	7	6	0	0	0	0
41	13	12	0	0	0	12	9	3	0	0	0	0
42	14	13	3	3	0	10	8	2	0	0	0	0
43	13	11	0	0	0	11	7	4	0	0	0	0
44	15	15	1	1	0	14	6	8	0	0	0	0
45 <NP>												
46	15	15	2	2	0	13	8	5	0	0	0	0
47	14	14	0	0	0	14	9	5	0	0	0	0
48	14	14	1	1	0	13	9	4	0	0	0	0
49	13	12	1	1	0	11	6	5	0	0	0	0
50	13	9	0	0	0	9	4	5	0	0	0	0
TOTAL	313	277	17	17	0	260	138	122	0	0	0	0
MEAN	13.6	12.0	0.7	0.7		11.3	6.0	5.3				
ST.DEV.	1.5	2.8	0.9	0.9		2.8	2.2	2.1				

Reason for Exclusion from Evaluation :
<NP> Non-Pregnant

REPRODUCTION DATA
GROUP 3 (30 MG/KG)

FEMALE	CORP. LUTEA	IMPL.	-EMBRYONIC DEATHS-- TOTAL	EMBR. STAGE	FETAL STAGE	FETUSES TOTAL	LIVE MALE	LIVE FEM.	DEAD MALE	DEAD FEM.	MALF. MALE	MALF. FEM.
51	15	13	2	2	0	11	4	7	0	0	0	1
52	13	11	0	0	0	11	4	7	0	0	0	0
53	15	13	2	2	0	11	8	3	0	0	0	0
54	12	12	1	1	0	11	5	6	0	0	0	0
55	16	15	0	0	0	15	5	10	0	0	0	0
56	13	11	0	0	0	11	4	7	0	0	0	0
57	16	14	1	1	0	13	8	5	0	0	0	0
58	13	11	0	0	0	11	6	5	0	0	0	0
59	16	14	0	0	0	14	8	6	0	0	0	0
60	14	12	2	2	0	10	5	5	0	0	0	0
61	9	9	0	0	0	9	3	6	0	0	0	0
62	14	14	1	1	0	13	7	6	0	0	0	0
63	12	10	1	1	0	9	5	4	0	0	0	0
64	11	11	1	1	0	10	5	5	0	0	0	0
65	13	12	0	0	0	12	5	7	0	0	0	0
66	12	10	0	0	0	10	5	5	0	0	0	0
67	14	11	0	0	0	11	4	7	0	0	0	0
68	15	14	2	2	0	12	5	7	0	0	0	0
69 <NP>												
70	12	12	1	1	0	11	7	4	0	0	0	0
71	14	14	1	1	0	13	6	7	0	0	0	0
72	12	11	2	2	0	9	4	5	0	0	0	0
73	13	13	3	2	1	10	6	4	0	0	0	0
74	15	15	2	2	0	13	5	8	0	0	0	0
75	12	12	1	1	0	11	4	7	0	0	0	0
TOTAL	321	294	23	22	1	271	128	143	0	0	0	1
MEAN	13.4	12.3	1.0	0.9	0.0	11.3	5.3	6.0				0.0
ST.DEV.	1.7	1.6	0.9	0.8	0.2	1.6	1.4	1.5				0.2

Reason for Exclusion from Evaluation :
<NP> Non-Pregnant

REPRODUCTION DATA
GROUP 4 (100 MG/KG)

FEMALE	CORP. LUTEA	IMPL.	-EMBRYONIC DEATHS-- TOTAL	EMBR. STAGE	FETAL STAGE	FETUSES TOTAL	LIVE MALE	LIVE FEM.	DEAD MALE	DEAD FEM.	MALF. MALE	MALF. FEM.
76	19	10	5	4	1	5	0	5	0	0	0	0
77	15	12	0	0	0	12	3	9	0	0	0	0
78	15	12	1	1	0	11	4	7	0	0	0	1
79	15	13	2	0	2	11	5	6	0	0	0	0
80	13	13	0	0	0	13	6	7	0	0	0	0
81	13	12	0	0	0	12	5	7	0	0	0	0
82	15	14	5	3	2	9	5	4	0	0	0	0
83	13	12	2	2	0	10	6	4	0	0	0	0
84	11	5	4	4	0	1	0	1	0	0	0	0
85	15	12	5	4	1	7	4	3	0	0	0	0
86	16	15	4	4	0	11	5	6	0	0	0	0
87	15	14	2	2	0	12	8	4	0	0	0	0
88	13	13	2	1	1	11	6	5	0	0	0	1
89	9	5	0	0	0	5	2	3	0	0	0	0
90 <NP>												
91	14	14	5	5	0	9	5	4	0	0	0	0
92	14	13	5	2	3	8	3	5	0	0	0	0
93	16	16	0	0	0	16	8	8	0	0	0	0
94	13	13	1	1	0	12	6	6	0	0	0	0
95	15	14	0	0	0	14	7	7	0	0	0	0
96	14	10	3	3	0	7	4	3	0	0	0	0
97	12	12	3	1	2	9	3	6	0	0	0	0
98	13	12	3	3	0	9	1	8	0	0	0	0
99	13	12	0	0	0	12	5	7	0	0	0	0
100	16	15	4	3	1	11	5	6	0	0	1	0
TOTAL	337	293	56	43	13	237	106	131	0	0	1	2
MEAN	14.0	12.2	2.3	1.8	0.5	9.9	4.4	5.5			0.0	0.1
ST.DEV.	2.0	2.6	1.9	1.7	0.9	3.2	2.2	1.9			0.2	0.3

Reason for Exclusion from Evaluation :
<NP> Non-Pregnant

RCC PROJECT 236114
SXX 0665 TECHNICAL

EXTERNAL EXAMINATION OF FETUSES

Group (mg/kg)	No. of fetuses examined	Type of abnormal finding	Individual data of fetus(es)*	Fetus(es) of litter number
1 (0)	295	Runt	454/2.48**/F	13
2 (10)	260	No abnormal findings		
3 (30)	271	Runt	97/2.3/F	51
4 (100)	237	Palatoschisis Tail slightly shortened and constricted Runt Palatoschisis partially slightly edematous, dysplastic lower jaw, arthrogryposis (both fore paws) claws of the fore and hind paws mostly missing	336/4.3/F 724/4.2/F 901/2.4/M 1053/4.4/M	78 88 97 100

VISCERAL EXAMINATION OF FETUSES (WILSON TECHNIQUE)

Group (mg/kg)	No. of fetuses examined	Type of abnormal finding	Individual data of fetus(es)*	Fetus(es) of litter number
1 (0)	139	No abnormal findings		
2 (10)	123	No abnormal findings		
3 (30)	127	No abnormal findings		
4 (100)	112	Confirmation of palatoschisis which was noted during external examination (see paragraph above)	336/4.3/F	78

* = Fetus number / body weight in grams / sex (M = male; F = female)
** = On page 75, the body weight of this fetus is 2.5 grams because the value in these tables are rounded off.

RCC PROJECT 236114
SXX 0665 TECHNICAL

SKELETAL EXAMINATION OF FETUSES (ABNORMAL FINDINGS)

Group (mg/kg)	No. of fetuses examined	— Type of abnormal finding	Individual data of fetus(es)*	Fetus(es) of litter number
1 (0)	156	Wavy ribs, nos. 8-13 (right side)	119/4.8/M	6
		Wavy ribs, nos. 10-13 (left side) nos. 6-13 (right side)	131/4.3/M	6
		Wavy ribs, nos. 9-13 (right side)	411/4.4/F	10
		Wavy ribs, nos. 6-13 (right side)	426/4.9/F	11
		Wavy ribs, nos. 9-13 (right side)	434/4.3/F	12
		Wavy ribs, nos. 4-13 (left and right side)	436/4.7/M	12
		Wavy ribs, nos. 4-13 (left side) nos. 5-13 (right side); incompletely ossified ossa frontale	442/4.3/F	12
		Wavy ribs, nos. 4-13 (left and right side)	444/4.6/M	12
2 (10)	137	No abnormal findings		
3 (30)	144	No abnormal findings		
4 (100)	125	Bipartite lumbar vertebral body no. 5	397/5.3/F	85
		Two supernumerary ribs (no. 15th) (left and right side)	897/4.8/M	96
		Confirmation of palatoschisis, arthrogryposis, dysplastic lower jaw; further: lower jaw and radius of the right fore leg curved, claws of the fore and hind paws mostly missing (present only claws of digits 3, fore paws and of digits 4, hind paws)	1053/4.4/M	100

* = Fetus number / body weight in grams / sex (M = male; F = female)

RCC PROJECT 236114
SXX 0665 TECHNICAL

Confidential

Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent

REP-SFS - 1
02-APR-90

SKELETAL EXAMINATION SUMMARY

	GROUP 1 0 MG/KG		GROUP 2 10 MG/KG		GROUP 3 30 MG/KG		GROUP 4 100 MG/KG	
NUMBER OF FETUSES EXAMINED	156		137		144		125	
UNLISTED FINDING(S) (SHOWN ON PREVIOUS PAGE(S))	8	5%	0	**	0	**	3	2%
CRANIUM								
INCOMPLETELY OSSIFIED								
OS OCCIPITALE	12	8%	22	16% *	23	16% *	36	29% **
OS PARIETALE, BILATERAL	1	1%	1	1%	0		2	2%
OS INTERPARIETALE	0		1	1%	0		0	
BIPARTITE								
OS OCCIPITALE	0		0		0		1	1%
CERVICAL VERTEBRAE								
NON-OSSIFIED								
CERVICAL VERTEBRA 1	23	15%	26	19%	36	25% *	47	38% **
CERVICAL VERTEBRA 2	19	12%	9	7%	8	6% *	13	10%
CERVICAL VERTEBRA 3	13	8%	7	5%	2	1% **	6	5%
CERVICAL VERTEBRA 4	4	3%	2	1%	0		4	3%
CERVICAL VERTEBRA 5	1	1%	2	1%	0		2	2%
DUMBBELL SHAPE								
CERVICAL VERTEBRA 1	21	13%	16	12%	22	15%	14	11%
BIPARTITE								
CERVICAL VERTEBRA 1	10	6%	14	10%	22	15% *	15	12%
STERNUM								
INCOMPLETELY OSSIFIED								
STERNEBRA 1	1	1%	0		7	5% *	12	10% **
STERNEBRA 2	42	27%	33	24%	59	41% **	60	48% **
STERNEBRA 3	1	1%	1	1%	8	6% *	8	6% **
STERNEBRA 4	9	6%	3	2%	27	19% **	21	17% **
STERNEBRA 5	101	65%	99	72%	106	74%	99	79% **
STERNEBRA 6	1	1%	2	1%	15	10% **	26	21% **
NON-OSSIFIED								
STERNEBRA 1	0		0		0		1	1%
STERNEBRA 2	0		1	1%	0		2	2%
STERNEBRA 3	0		0		0		1	1%
STERNEBRA 5	1	1%	0		0		0	
STERNEBRA 6	0		0		3	2%	12	10% **
BIPARTITE								
STERNEBRA 1	0		0		1	1%	0	
STERNEBRA 2	0		0		1	1%	0	
STERNEBRA 3	0		0		0		1	1%
STERNEBRA 4	0		0		1	1%	0	
STERNEBRA 5	0		0		1	1%	0	
STERNEBRA 6	0		0		1	1%	0	
ABNORMALLY OSSIFIED								
STERNEBRA 2	0		0		1	1%	0	
STERNEBRA 4	2	1%	0		0		1	1%
STERNEBRA 5	1	1%	0		1	1%	2	2%
STERNEBRA 6	0		0		1	1%	0	
RIB(S), LEFT								
SUPERNUMERARY, ONE RIB(S), LEFT	33	21%	64	47% **	108	75% **	95	76% **
RIB(S), RIGHT								
SUPERNUMERARY, ONE RIB(S), RIGHT	30	19%	64	47% **	106	74% **	93	74% **

* / ** : Fisher's Exact test significant at 5% (*) or 1% (**) level

SKELETAL EXAMINATION SUMMARY

	GROUP 1 0 MG/KG		GROUP 2 10 MG/KG		GROUP 3 30 MG/KG		GROUP 4 100 MG/KG	
NUMBER OF FETUSES EXAMINED	156		137		144		125	
LEFT FORELIMB								
NON-OSSIFIED								
DIGIT 1 DISTAL PHALANX, LEFT	3	2%	0		2	1%	0	
DIGIT 2 PROXIMAL PHALANX, LEFT	65	42%	41	30% *	52	36%	92	74% **
DIGIT 2 DISTAL PHALANX, LEFT	18	12%	13	9%	15	10%	7	6%
DIGIT 3 PROXIMAL PHALANX, LEFT	3	2%	1	1%	3	2%	4	3%
DIGIT 3 DISTAL PHALANX, LEFT	2	1%	1	1%	2	1%	0	
DIGIT 4 PROXIMAL PHALANX, LEFT	6	4%	1	1%	4	3%	9	7%
DIGIT 4 DISTAL PHALANX, LEFT	10	6%	5	4%	7	5%	3	2%
METACARPALIA 5, LEFT	0		0		0		1	1%
DIGIT 5 PROXIMAL PHALANX, LEFT	95	61%	63	46% **	85	59%	106	85% **
DIGIT 5 DISTAL PHALANX, LEFT	56	36%	45	33%	44	31%	26	21% **
RIGHT FORELIMB								
NON-OSSIFIED								
DIGIT 1 DISTAL PHALANX, RIGHT	2	1%	0		2	1%	0	
DIGIT 2 PROXIMAL PHALANX, RIGHT	61	39%	38	28% *	50	35%	90	72% **
DIGIT 2 DISTAL PHALANX, RIGHT	14	9%	10	7%	15	10%	5	4%
DIGIT 3 PROXIMAL PHALANX, RIGHT	2	1%	0		2	1%	2	2%
DIGIT 3 DISTAL PHALANX, RIGHT	1	1%	0		3	2%	0	
DIGIT 4 PROXIMAL PHALANX, RIGHT	4	3%	2	1%	4	3%	6	5%
DIGIT 4 DISTAL PHALANX, RIGHT	6	4%	4	3%	8	6%	4	3%
METACARPALIA 5, RIGHT	0		0		0		1	1%
DIGIT 5 PROXIMAL PHALANX, RIGHT	93	60%	64	47% *	83	58%	107	86% **
DIGIT 5 DISTAL PHALANX, RIGHT	53	34%	47	34%	43	30%	20	16% **
LEFT HIND LIMB								
NON-OSSIFIED								
TALUS LEFT	140	90%	113	82%	127	88%	109	87%
METATARSALIA 1, LEFT	23	15%	7	5% **	9	6% *	26	21%
TOE 1 DISTAL PHALANX, LEFT	3	2%	0		1	1%	1	1%
TOE 2 PROXIMAL PHALANX, LEFT	128	82%	99	72% *	121	84%	118	94% **
TOE 3 PROXIMAL PHALANX, LEFT	86	55%	92	67% *	120	83% **	118	94% **
TOE 4 PROXIMAL PHALANX, LEFT	83	53%	78	57%	121	84% **	116	93% **
TOE 4 DISTAL PHALANX, LEFT	1	1%	0		0		0	
TOE 5 PROXIMAL PHALANX, LEFT	146	94%	121	88%	134	93%	120	96%
TOE 5 DISTAL PHALANX, LEFT	2	1%	1	1%	2	1%	0	
RIGHT HIND LIMB								
NON-OSSIFIED								
TALUS RIGHT	140	90%	118	86%	131	91%	114	91%
METATARSALIA 1, RIGHT	23	15%	6	4% **	9	6% *	27	22%
TOE 1 DISTAL PHALANX, RIGHT	3	2%	0		0		2	2%
TOE 2 PROXIMAL PHALANX, RIGHT	130	83%	105	77%	126	88%	120	96% **
TOE 2 DISTAL PHALANX, RIGHT	1	1%	0		0		0	
TOE 3 PROXIMAL PHALANX, RIGHT	91	58%	93	68%	127	88% **	123	98% **
TOE 3 DISTAL PHALANX, RIGHT	1	1%	0		0		0	
TOE 4 PROXIMAL PHALANX, RIGHT	89	57%	84	61%	123	85% **	122	98% **
TOE 5 PROXIMAL PHALANX, RIGHT	143	92%	125	91%	137	95%	124	99% **
TOE 5 DISTAL PHALANX, RIGHT	2	1%	1	1%	1	1%	0	

* / ** : Fisher's Exact test significant at 5% (*) or 1% (**) level

Confidential
Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

SKELETAL EXAMINATION SUMMARY

	GROUP 1 0 MG/KG	GROUP 2 10 MG/KG	GROUP 3 30 MG/KG	GROUP 4 100 MG/KG
NUMBER OF LITTERS EXAMINED	25	23	24	24
UNLISTED FINDING(S) (SHOWN ON PREVIOUS PAGE(S))	4 16%	0	0	3 13%
CRANIUM				
INCOMPLETELY OSSIFIED				
OS OCCIPITALE	8 32%	12 52%	12 50%	19 79% **
OS PARIETALE, BILATERAL	1 4%	1 4%	0	2 8%
OS INTERPARIETALE	0	1 4%	0	0
BIPARTITE				
OS OCCIPITALE	0	0	0	1 4%
CERVICAL VERTEBRAE				
NON-OSSIFIED				
CERVICAL VERTEBRA 1	15 60%	16 70%	20 83%	20 83%
CERVICAL VERTEBRA 2	10 40%	5 22%	7 29%	8 33%
CERVICAL VERTEBRA 3	8 32%	5 22%	2 8% *	4 17%
CERVICAL VERTEBRA 4	4 16%	2 9%	0	3 13%
CERVICAL VERTEBRA 5	1 4%	2 9%	0	1 4%
DUMBBELL SHAPE				
CERVICAL VERTEBRA 1	14 56%	9 39%	16 67%	10 42%
BIPARTITE				
CERVICAL VERTEBRA 1	8 32%	11 48%	13 54%	9 38%
STERNUM				
INCOMPLETELY OSSIFIED				
STERNEBRA 1	1 4%	0	6 25% *	8 33% **
STERNEBRA 2	20 80%	13 57%	22 92%	19 79%
STERNEBRA 3	1 4%	1 4%	5 21%	5 21%
STERNEBRA 4	8 32%	3 13%	18 75% **	13 54%
STERNEBRA 5	24 96%	22 96%	24 100%	23 96%
STERNEBRA 6	1 4%	2 9%	10 42% **	14 58% **
NON-OSSIFIED				
STERNEBRA 1	0	0	0	1 4%
STERNEBRA 2	0	1 4%	0	2 8%
STERNEBRA 3	0	0	0	1 4%
STERNEBRA 5	1 4%	0	0	0
STERNEBRA 6	0	0	3 13%	8 33% **
BIPARTITE				
STERNEBRA 1	0	0	1 4%	0
STERNEBRA 2	0	0	1 4%	0
STERNEBRA 3	0	0	0	1 4%
STERNEBRA 4	0	0	1 4%	0
STERNEBRA 5	0	0	1 4%	0
STERNEBRA 6	0	0	1 4%	0
ABNORMALLY OSSIFIED				
STERNEBRA 2	0	0	1 4%	0
STERNEBRA 4	2 8%	0	0	1 4%
STERNEBRA 5	1 4%	0	1 4%	1 4%
STERNEBRA 6	0	0	1 4%	0
RIB(S), LEFT				
SUPERNUMERARY, ONE RIB(S), LEFT	17 68%	20 87%	24 100% **	23 96% *
RIB(S), RIGHT				
SUPERNUMERARY, ONE RIB(S), RIGHT	16 64%	20 87%	24 100% **	23 96% **

* / ** : Fisher's Exact test significant at 5% (*) or 1% (**) level

SKELETAL EXAMINATION SUMMARY

	GROUP 1 0 MG/KG	GROUP 2 10 MG/KG	GROUP 3 30 MG/KG	GROUP 4 100 MG/KG
NUMBER OF LITTERS EXAMINED	25	23	24	24
LEFT FORELIMB				
NON-OSSIFIED				
DIGIT 1 DISTAL PHALANX, LEFT	2 8%	0	2 8%	0
DIGIT 2 PROXIMAL PHALANX, LEFT	21 84%	17 74%	19 79%	22 92%
DIGIT 2 DISTAL PHALANX, LEFT	10 40%	7 30%	9 38%	6 25%
DIGIT 3 PROXIMAL PHALANX, LEFT	2 8%	1 4%	3 13%	3 13%
DIGIT 3 DISTAL PHALANX, LEFT	1 4%	1 4%	2 8%	0
DIGIT 4 PROXIMAL PHALANX, LEFT	3 12%	1 4%	3 13%	5 21%
DIGIT 4 DISTAL PHALANX, LEFT	6 24%	3 13%	6 25%	3 13%
METACARPALIA 5, LEFT	0	0	0	1 4%
DIGIT 5 PROXIMAL PHALANX, LEFT	25 100%	20 87%	22 92%	23 96%
DIGIT 5 DISTAL PHALANX, LEFT	20 80%	17 74%	14 58%	13 54%
RIGHT FORELIMB				
NON-OSSIFIED				
DIGIT 1 DISTAL PHALANX, RIGHT	1 4%	0	2 8%	0
DIGIT 2 PROXIMAL PHALANX, RIGHT	20 80%	17 74%	21 88%	22 92%
DIGIT 2 DISTAL PHALANX, RIGHT	9 36%	6 26%	9 38%	4 17%
DIGIT 3 PROXIMAL PHALANX, RIGHT	2 8%	0	2 8%	2 8%
DIGIT 3 DISTAL PHALANX, RIGHT	1 4%	0	3 13%	0
DIGIT 4 PROXIMAL PHALANX, RIGHT	2 8%	2 9%	2 8%	5 21%
DIGIT 4 DISTAL PHALANX, RIGHT	4 16%	3 13%	8 33%	4 17%
METACARPALIA 5, RIGHT	0	0	0	1 4%
DIGIT 5 PROXIMAL PHALANX, RIGHT	25 100%	20 87%	22 92%	23 96%
DIGIT 5 DISTAL PHALANX, RIGHT	19 76%	17 74%	15 63%	10 42% *
LEFT HIND LIMB				
NON-OSSIFIED				
TALUS LEFT	25 100%	22 96%	24 100%	24 100%
METATARSALIA 1, LEFT	15 60%	7 30% *	6 25% *	11 46%
TOE 1 DISTAL PHALANX, LEFT	2 8%	0	1 4%	1 4%
TOE 2 PROXIMAL PHALANX, LEFT	25 100%	21 91%	23 96%	24 100%
TOE 3 PROXIMAL PHALANX, LEFT	23 92%	21 91%	23 96%	24 100%
TOE 4 PROXIMAL PHALANX, LEFT	23 92%	20 87%	23 96%	24 100%
TOE 4 DISTAL PHALANX, LEFT	1 4%	0	0	0
TOE 5 PROXIMAL PHALANX, LEFT	25 100%	22 96%	24 100%	24 100%
TOE 5 DISTAL PHALANX, LEFT	2 8%	1 4%	2 8%	0
RIGHT HIND LIMB				
NON-OSSIFIED				
TALUS RIGHT	25 100%	22 96%	24 100%	24 100%
METATARSALIA 1, RIGHT	15 60%	6 26% *	6 25% *	13 54%
TOE 1 DISTAL PHALANX, RIGHT	2 8%	0	0	2 8%
TOE 2 PROXIMAL PHALANX, RIGHT	25 100%	22 96%	23 96%	24 100%
TOE 2 DISTAL PHALANX, RIGHT	1 4%	0	0	0
TOE 3 PROXIMAL PHALANX, RIGHT	23 92%	21 91%	23 96%	24 100%
TOE 3 DISTAL PHALANX, RIGHT	1 4%	0	0	0
TOE 4 PROXIMAL PHALANX, RIGHT	23 92%	21 91%	23 96%	24 100%
TOE 5 PROXIMAL PHALANX, RIGHT	25 100%	22 96%	24 100%	24 100%
TOE 5 DISTAL PHALANX, RIGHT	2 8%	1 4%	1 4%	0

* / ** : Fisher's Exact test significant at 5% (*) or 1% (**) level

BODY WEIGHTS OF LIVE FETUSES SUMMARY (PER DAM)
GROUP 1 (0 MG/KG)

LITTER	- MALES AND FEMALES - N	MEAN	ST.DEV.	------- MALES ------- N	MEAN	ST.DEV.	------ FEMALES ------ N	MEAN	ST.DEV.
1	13	5.0	0.2	4	5.1	0.2	9	4.9	0.2
2	9	5.2	0.1	5	5.2	0.1	4	5.1	0.1
3	15	4.4	0.3	7	4.3	0.4	8	4.4	0.2
4	13	4.8	0.3	10	4.9	0.3	3	4.3	0.2
5	14	4.8	0.3	7	5.0	0.1	7	4.7	0.2
6	13	4.8	0.3	9	4.9	0.3	4	4.7	0.2
7	12	4.7	0.3	3	5.0	0.3	9	4.6	0.2
8	11	4.9	0.2	6	5.1	0.1	5	4.8	0.2
9	11	4.7	0.3	7	4.8	0.3	4	4.5	0.3
10	11	4.7	0.3	5	4.6	0.3	6	4.7	0.2
11	10	4.8	0.3	4	5.1	0.2	6	4.7	0.1
12	13	4.4	0.3	9	4.6	0.2	4	4.1	0.4
13	10	4.2	0.7	4	4.4	0.5	6	4.0	0.9
14	12	5.0	0.2	6	5.1	0.2	6	4.9	0.3
15	11	5.4	0.3	6	5.4	0.4	5	5.3	0.2
16	13	4.9	0.2	8	5.0	0.1	5	4.7	0.3
17	14	4.4	0.2	4	4.6	0.1	10	4.3	0.2
18	11	4.6	0.4	4	4.9	0.3	7	4.4	0.4
19	8	5.3	0.3	5	5.5	0.2	3	5.0	0.3
20	13	4.9	0.2	3	4.9	0.3	10	4.9	0.2
21	13	4.7	0.1	7	4.8	0.1	6	4.7	0.1
22	12	4.5	0.3	3	4.5	0.5	9	4.5	0.3
23	12	5.0	0.3	6	5.0	0.2	6	4.9	0.3
24	10	4.9	0.2	6	5.1	0.1	4	4.7	0.2
25	11	4.7	0.2	7	4.7	0.2	4	4.7	0.2
N	295	25		145	25		150	25	
MEAN	11.8	4.8		5.8	4.9		6.0	4.7	
ST.DEV.	1.7	0.3		2.0	0.3		2.1	0.3	

<EX> : Animal Excluded from Evaluation

BODY WEIGHTS OF LIVE FETUSES SUMMARY (PER DAM)
GROUP 2 (10 MG/KG)

LITTER	- MALES AND FEMALES - N	MEAN	ST.DEV.	------- MALES ------- N	MEAN	ST.DEV.	------ FEMALES ------ N	MEAN	ST.DEV.
26	13	5.3	0.2	7	5.4	0.2	6	5.2	0.2
27	13	4.8	0.3	6	5.0	0.1	7	4.6	0.3
28	1	6.0		1	6.0		0		
29	8	5.0	0.2	5	5.1	0.2	3	4.9	0.1
30 <EX>									
31	11	4.5	0.2	5	4.6	0.3	6	4.4	0.1
32	9	5.4	0.3	2	5.5	0.4	7	5.3	0.2
33	12	4.8	0.2	6	4.9	0.2	6	4.7	0.2
34	11	4.9	0.2	7	4.9	0.2	4	4.9	0.1
35	12	4.8	0.4	2	5.0	0.3	10	4.8	0.4
36	12	4.6	0.6	5	4.6	0.9	7	4.7	0.3
37	12	5.0	0.2	6	5.1	0.1	6	4.9	0.2
38	13	5.2	0.3	7	5.3	0.3	6	5.0	0.2
39	13	4.9	0.6	6	5.2	0.3	7	4.6	0.6
40	13	4.8	0.2	7	4.9	0.2	6	4.8	0.3
41	12	4.6	0.3	9	4.6	0.2	3	4.3	0.4
42	10	4.9	0.3	8	5.0	0.2	2	4.4	0.0
43	11	4.8	0.3	7	4.8	0.2	4	4.7	0.4
44	14	5.3	0.3	6	5.5	0.3	8	5.2	0.2
45 <EX>									
46	13	4.6	0.2	8	4.6	0.2	5	4.5	0.1
47	14	4.4	0.3	9	4.5	0.2	5	4.3	0.4
48	13	4.8	0.3	9	4.8	0.3	4	4.8	0.2
49	11	4.8	0.4	6	5.0	0.4	5	4.5	0.3
50	9	4.9	0.3	4	5.1	0.2	5	4.8	0.3
N	260	23		138	23		122	22	
MEAN	11.3	4.9		6.0	5.0		5.3	4.7	
ST.DEV.	2.8	0.3		2.2	0.3		2.1	0.3	

Confidential
Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

<EX> : Animal Excluded from Evaluation

BODY WEIGHTS OF LIVE FETUSES SUMMARY (PER DAM)
GROUP 3 (30 MG/KG)

LITTER	- MALES AND FEMALES - N	MEAN	ST.DEV.	------- MALES ------- N	MEAN	ST.DEV.	------ FEMALES ------ N	MEAN	ST.DEV.
51	11	4.7	1.0	4	5.0	0.9	7	4.6	1.0
52	11	4.9	0.3	4	5.1	0.3	7	4.9	0.2
53	11	4.7	0.4	8	4.9	0.3	3	4.4	0.3
54	11	4.6	0.3	5	4.8	0.3	6	4.5	0.3
55	15	4.8	0.4	5	5.0	0.2	10	4.6	0.4
56	11	4.9	0.4	4	5.1	0.2	7	4.7	0.4
57	13	4.8	0.3	8	4.9	0.3	5	4.7	0.1
58	11	4.4	0.3	6	4.5	0.3	5	4.4	0.3
59	14	4.9	0.3	8	5.0	0.2	6	4.6	0.2
60	10	5.0	0.5	5	5.2	0.5	5	4.8	0.4
61	9	5.1	0.2	3	5.1	0.2	6	5.0	0.2
62	13	5.0	0.5	7	5.3	0.3	6	4.6	0.4
63	9	5.3	0.3	5	5.4	0.3	4	5.2	0.3
64	10	5.1	0.3	5	5.1	0.4	5	5.1	0.2
65	12	5.3	0.4	5	5.7	0.2	7	5.1	0.2
66	10	5.1	0.3	5	5.2	0.2	5	4.9	0.2
67	11	4.6	0.3	4	4.7	0.3	7	4.5	0.3
68	12	4.9	0.4	5	5.2	0.2	7	4.7	0.3
69 <EX>									
70	11	5.2	0.3	7	5.4	0.1	4	4.8	0.1
71	13	5.3	0.3	6	5.4	0.3	7	5.1	0.2
72	9	5.3	0.2	4	5.4	0.2	5	5.2	0.1
73	10	4.4	0.7	6	4.2	0.9	4	4.7	0.2
74	13	4.9	0.2	5	5.0	0.2	8	4.9	0.2
75	11	4.6	0.2	4	4.8	0.2	7	4.5	0.2
N	271	24		128	24		143	24	
MEAN	11.3	4.9		5.3	5.1		6.0	4.8	
ST.DEV.	1.6	0.3		1.4	0.3		1.5	0.2	

<EX> : Animal Excluded from Evaluation

BODY WEIGHTS OF LIVE FETUSES SUMMARY (PER DAM)
GROUP 4 (100 MG/KG)

LITTER	- MALES AND FEMALES - N	MEAN	ST.DEV.	------- MALES ------- N	MEAN	ST.DEV.	------ FEMALES ------ N	MEAN	ST.DEV.
76	5	4.7	0.2	0			5	4.7	0.2
77	12	4.9	0.3	3	5.1	0.2	9	4.8	0.3
78	11	5.0	0.5	4	5.0	0.7	7	5.0	0.3
79	11	4.2	0.5	5	4.3	0.6	6	4.2	0.4
80	13	4.9	0.3	6	5.0	0.4	7	4.8	0.3
81	12	5.0	0.2	5	5.1	0.2	7	5.0	0.2
82	9	4.1	0.4	5	4.2	0.1	4	3.9	0.6
83	10	4.9	0.4	6	4.8	0.5	4	5.0	0.2
84	1	5.0		0			1	5.0	
85	7	5.0	0.7	4	4.9	0.9	3	5.1	0.2
86	11	5.2	0.5	5	5.3	0.7	6	5.0	0.2
87	12	4.7	0.3	8	4.7	0.4	4	4.6	0.1
88	11	5.2	0.6	6	5.6	0.2	5	4.7	0.4
89	5	5.5	0.4	2	5.6	0.3	3	5.4	0.5
90 <EX>									
91	9	4.5	0.3	5	4.6	0.3	4	4.4	0.4
92	8	4.6	0.5	3	4.9	0.5	5	4.4	0.5
93	16	4.6	0.2	8	4.7	0.2	8	4.5	0.2
94	12	4.6	0.3	6	4.6	0.3	6	4.6	0.3
95	14	4.7	0.6	7	4.9	0.4	7	4.5	0.6
96	7	4.8	0.2	4	4.8	0.1	3	4.8	0.3
97	9	4.0	0.8	3	3.1	0.7	6	4.5	0.3
98	9	4.8	0.6	1	5.4		8	4.7	0.6
99	12	5.0	0.2	5	5.2	0.2	7	4.9	0.2
100	11	4.2	0.7	5	4.4	1.0	6	4.1	0.4
N	237	24		106	22		131	24	
MEAN	9.9	4.7		4.4	4.8		5.5	4.7	
ST.DEV.	3.2	0.4		2.2	0.5		1.9	0.3	

<EX> : Animal Excluded from Evaluation

DISTRIBUTION WITHIN UTERUS
GROUP 1 (0 MG/KG)

LEFT HORN						POSITION	RIGHT HORN					
IMPLAN-TATIONS	EMPTY SITES	RESORPTIONS EMBR.	RESORPTIONS FETAL	FETUSES DEAD	FETUSES LIVE	IN UTERUS	FETUSES LIVE	FETUSES DEAD	RESORPTIONS FETAL	RESORPTIONS EMBR.	EMPTY SITES	IMPLAN-TATIONS
25	.	.	.	.	25	< 1>	25	.	.	.	.	25
25	.	1	.	.	24	< 2>	25	.	.	.	.	25
25	.	2	.	.	23	< 3>	22	.	.	2	.	24
25	.	.	.	.	25	< 4>	20	.	.	2	.	22
23	.	2	.	.	21	< 5>	18	.	.	.	.	18
20	.	2	.	.	18	< 6>	12	.	1	.	.	13
17	.	.	.	.	17	< 7>	6	.	.	.	.	6
5	.	.	.	.	5	< 8>	4	.	.	.	.	4
2	.	.	.	.	2	< 9>	1	.	.	.	.	1
1	.	.	.	.	1	<10>						
1	.	.	.	.	1	<11>						

IMPLANTATION SITES

```
25 ========================= < 1> ========================= 25
25 ========================= < 2> ========================= 25
25 ========================= < 3> ======================== 24
25 ========================= < 4> ====================== 22
  23 ======================= < 5> ================= 18
     20 ==================== < 6> ============ 13
        17 ================= < 7> ====== 6
                       5 ===== < 8> ==== 4
                          2 == < 9> = 1
                            1 = <10>
                            1 = <11>
```

LIVE FETUSES

```
25 ========================= < 1> ========================= 25
 24 ======================== < 2> ======================== 25
  23 ======================= < 3> ====================== 22
25 ========================= < 4> ================== 20
    21 ===================== < 5> ================ 18
       18 ================== < 6> ========== 12
        17 ================= < 7> ====== 6
                       5 ===== < 8> ==== 4
                          2 == < 9> = 1
                            1 = <10>
                            1 = <11>
```

RESORPTIONS

```
      < 1>
    1 = < 2>
    2 == < 3> == 2
      < 4> == 2
    2 == < 5>
    2 == < 6> = 1
      < 7>
      < 8>
      < 9>
      <10>
      <11>
```

RCC PROJECT 236114
SXX 0665 TECHNICAL

CAE-DIST - 2
25-APR-91

Confidential

Copyright by Bayer AG
the use, utilization or distribution
is only permitted with the consent
of Bayer AG

DISTRIBUTION WITHIN UTERUS
GROUP 2 (10 MG/KG)

LEFT HORN						POSITION	RIGHT HORN					
IMPLAN-TATIONS	EMPTY SITES	RESORPTIONS EMBR.	RESORPTIONS FETAL	FETUSES DEAD	FETUSES LIVE	IN UTERUS	FETUSES LIVE	FETUSES DEAD	RESORPTIONS FETAL	RESORPTIONS EMBR.	EMPTY SITES	IMPLAN-TATIONS
23	.	1	.	.	22	< 1>	21	.	.	1	.	22
22	.	1	.	.	21	< 2>	20	.	.	2	.	22
22	.	2	.	.	20	< 3>	22	.	.	.	.	22
20	.	2	.	.	18	< 4>	21	.	.	1	.	22
15	.	2	.	.	13	< 5>	18	.	.	1	.	19
13	.	1	.	.	12	< 6>	14	.	.	1	.	15
8	.	.	.	.	8	< 7>	10	.	.	.	.	10
7	.	2	.	.	5	< 8>	6	.	.	.	.	6
2	.	.	.	.	2	< 9>	4	.	.	.	.	4
						<10>	2	.	.	.	.	2
						<11>	1	.	.	.	.	1

IMPLANTATION SITES

```
23 ======================= < 1> ======================= 22
 22 ======================= < 2> ======================= 22
 22 ======================= < 3> ======================= 22
   20 ====================== < 4> ======================= 22
        15 ================ < 5> ================== 19
          13 ============== < 6> ================ 15
                8 ======== < 7> ========== 10
                 7 ======= < 8> ====== 6
                      2 == < 9> ==== 4
                           <10> == 2
                           <11> = 1
```

LIVE FETUSES

```
22 ======================= < 1> ======================= 21
 21 ======================= < 2> ====================== 20
  20 ====================== < 3> ======================== 22
    18 ================== < 4> ======================= 21
         13 ============== < 5> ================== 18
          12 ============ < 6> ============== 14
                8 ======== < 7> ========== 10
                   5 ===== < 8> ====== 6
                      2 == < 9> ==== 4
                           <10> == 2
                           <11> = 1
```

RESORPTIONS

```
 1 = < 1> = 1
 1 = < 2> == 2
2 == < 3>
2 == < 4> = 1
2 == < 5> = 1
 1 = < 6> = 1
     < 7>
2 == < 8>
     < 9>
     <10>
     <11>
```

DISTRIBUTION WITHIN UTERUS
GROUP 3 (30 MG/KG)

LEFT HORN							POSITION	RIGHT HORN					
IMPLAN-TATIONS	EMPTY SITES	RESORPTIONS EMBR.	RESORPTIONS FETAL	FETUSES DEAD	FETUSES LIVE		IN UTERUS	FETUSES LIVE	FETUSES DEAD	RESORPTIONS FETAL	RESORPTIONS EMBR.	EMPTY SITES	IMPLAN-TATIONS
24	.	.	.	.	24		< 1>	23	.	.	1	.	24
24	.	4	.	.	20		< 2>	23	.	.	1	.	24
22	.	3	.	.	19		< 3>	22	.	.	1	.	23
21	.	2	.	.	19		< 4>	20	.	.	1	.	21
20	.	3	.	.	17		< 5>	18	.	.	1	.	19
18	.	1	.	.	17		< 6>	11	.	.	2	.	13
15	.	.	.	.	15		< 7>	6	.	.	.	.	6
8	.	2	.	.	6		< 8>	2	.	.	.	.	2
4	.	.	1	.	3		< 9>	1	.	.	.	.	1
2	.	.	.	.	2		<10>						
2	.	.	.	.	2		<11>						
1	.	.	.	.	1		<12>						

IMPLANTATION SITES

```
24 ======================== < 1> ========================  24
24 ======================== < 2> ========================  24
  22 ======================= < 3> ======================  23
   21 ====================== < 4> ===================== 21
    20 ===================== < 5> ================== 19
      18 ================== < 6> ============ 13
         15 =============== < 7> ====== 6
                   8 ======== < 8> == 2
                       4 ==== < 9> = 1
                         2 == <10>
                         2 == <11>
                          1 = <12>
```

LIVE FETUSES

```
24 ======================== < 1> ======================  23
    20 ===================== < 2> ======================  23
     19 ==================== < 3> ====================  22
     19 ==================== < 4> ================== 20
       17 ================= < 5> ================ 18
       17 ================= < 6> ========== 11
         15 =============== < 7> ====== 6
                   6 ====== < 8> == 2
                      3 === < 9> = 1
                         2 == <10>
                         2 == <11>
                          1 = <12>
```

RESORPTIONS

```
                         < 1> = 1
                       4 ==== < 2> = 1
                      3 === < 3> = 1
                       2 == < 4> = 1
                      3 === < 5> = 1
                        1 = < 6> == 2
                         < 7>
                       2 == < 8>
                        1 = < 9>
                         <10>
                         <11>
                         <12>
```

RCC PROJECT 236114
SXX 0665 TECHNICAL

Confidential

Copyright by Bayer AG
the use, publication or distribution
is only permitted with the consent
of Bayer AG

CAE-DIST - 4
25-APR-91

DISTRIBUTION WITHIN UTERUS
GROUP 4 (100 MG/KG)

LEFT HORN						POSITION	RIGHT HORN					
IMPLAN-TATIONS	EMPTY SITES	RESORPTIONS EMBR.	RESORPTIONS FETAL	FETUSES DEAD	FETUSES LIVE	IN UTERUS	FETUSES LIVE	FETUSES DEAD	RESORPTIONS FETAL	RESORPTIONS EMBR.	EMPTY SITES	IMPLAN-TATIONS
24	.	2	3	.	19	< 1>	20	.	1	3	.	24
23	.	.	.	.	23	< 2>	18	.	.	6	.	24
22	.	3	2	.	17	< 3>	21	.	.	3	.	24
20	.	1	3	.	16	< 4>	17	.	.	5	.	22
20	.	3	.	.	17	< 5>	15	.	1	3	.	19
19	.	3	.	.	16	< 6>	7	.	2	5	.	14
16	.	3	.	.	13	< 7>	5	.	1	1	.	7
8	.	2	.	.	6	< 8>	4	.	.	.	.	4
2	.	.	.	.	2	< 9>	1	.	.	.	.	1

IMPLANTATION SITES

```
24 ======================== < 1> ========================  24
 23 ======================= < 2> ========================  24
  22 ======================= < 3> ========================  24
    20 ====================== < 4> ======================  22
    20 ====================== < 5> ===================  19
     19 ===================== < 6> ==============  14
        16 ================= < 7> =======  7
                 8 ========  < 8> ====  4
                      2 ==  < 9> =  1
```

LIVE FETUSES

```
     19 ==================== < 1> ====================  20
 23 ======================== < 2> ==================  18
        17 ================= < 3> ======================  21
         16 ================ < 4> ================  17
        17 ================= < 5> ==============  15
         16 ================ < 6> =======  7
            13 ============= < 7> =====  5
                     6 ======  < 8> ====  4
                        2 ==  < 9> =  1
```

RESORPTIONS

```
5 =====  < 1> ====  4
         < 2> ======  6
5 =====  < 3> ===  3
 4 ====  < 4> =====  5
  3 ===  < 5> ====  4
  3 ===  < 6> =======  7
  3 ===  < 7> ==  2
   2 ==  < 8>
         < 9>
```

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 1 (0 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES (POS. IN UTERUS)			FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 1													
6/8	1	F	5.0		A	LIVE	<1>	LIVE	6	F	5.3		W
	2	F	4.7		W	LIVE	<2>	LIVE	7	M	5.0		A
	3	F	4.8		A	LIVE	<3>	LIVE	8	F	4.8		W
	4	M	4.9		W	LIVE	<4>	LIVE	9	F	5.0		A
	5	F	4.9		A	LIVE	<5>	LIVE	10	F	5.0		W
							<6>	LIVE	11	M	5.4		A
							<7>	LIVE	12	F	4.7		W
							<8>	LIVE	13	M	5.0		A
FEMALE 2													
8/4	14	M	5.4		A	LIVE	<1>	LIVE	21	F	5.1		W
	15	F	5.0		A	LIVE	<2>	LIVE	22	M	5.3		A
	16	F	5.2		A	LIVE	<3>						
	17	M	5.1		W	LIVE	<4>						
	18	M	5.1		A	LIVE	<5>						
	19	F	5.2		W	LIVE	<6>						
	20	M	5.3		A	LIVE	<7>						
FEMALE 3													
8/9	23	F	4.6		A	LIVE	<1>	LIVE	30	F	4.7		W
	24	M	4.5		W	LIVE	<2>	LIVE	31	F	4.2		A
	25	M	4.5		A	LIVE	<3>	LIVE	32	M	4.5		W
	26	F	4.5		W	LIVE	<4>	LIVE	33	M	4.3		A
	27	F	4.3		A	LIVE	<5>	LIVE	34	F	4.3		W
	28	M	4.9		W	LIVE	<6>	LIVE	35	M	3.8		A
	29	F	4.4		A	LIVE	<7>	LIVE	36	M	3.7		W
							<8>	LIVE	37	F	4.5		A
FEMALE 4													
8/7	38	F	4.4		A	LIVE	<1>	LIVE	45	M	5.2		W
	39	M	4.6		W	LIVE	<2>	LIVE	46	M	5.0		A
	40	M	5.2		A	LIVE	<3>	LIVE	47	M	4.8		W
	41	M	5.0		W	LIVE	<4>	LIVE	48	F	4.5		A
	42	M	4.5		A	LIVE	<5>	LIVE	49	M	5.1		W
	43	M	4.7		W	LIVE	<6>	LIVE	50	F	4.1		A
	44	M	4.7		A	LIVE	<7>						
FEMALE 5													
12/3	51	M	5.1		A	LIVE	<1>	LIVE	62	F	4.8		W
	52	M	5.0		W	LIVE	<2>	LIVE	63	F	4.7		A
	53	M	4.8		A	LIVE	<3>	LIVE	64	M	5.0		W
	54	F	4.3		W	LIVE	<4>						
	55	M	4.9		A	LIVE	<5>						
	56	M	5.2		W	LIVE	<6>						
	57	M	4.8		A	LIVE	<7>						
	58	F	5.0		W	LIVE	<8>						
	59	F	4.8		A	LIVE	<9>						
	60	F	4.4		W	LIVE	<10>						
	61	F	4.5		A	LIVE	<11>						
FEMALE 6													
6/9	119	M	4.8		A	LIVE	<1>	LIVE	124	F	4.4		W
	120	M	5.1		W	LIVE	<2>	LIVE	125	M	5.1		A
	121	M	5.1		A	LIVE	<3>	LIVE	126	M	5.2		W
	122	M	5.1		W	LIVE	<4>	LIVE	127	F	5.0		A
	123	F	4.7		A	LIVE	<5>	LIVE	128	M	4.8		W
							<6>	LIVE	129	M	4.9		A
							<7>	LIVE	130	F	4.6		W
							<8>	LIVE	131	M	4.5		A

LIVE - LIVE FETUS E.RES - EMBRYONIC RESORPTION W - WILSON SLICING TECHNIQUE
DEAD - DEAD FETUS F.RES - FETAL RESORPTION A - ALIZARIN RED S SKELETAL STAINING TECHN.

Confidential

Copyright by Bayer AG
[illegible]

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 1 (0 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES <POS. IN UTERUS>	FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 7											
6/7	132	M	4.7		A	LIVE <1> LIVE	138	M	5.0		A
	133	F	4.3		W	LIVE <2> LIVE	139	M	5.4		W
	134	F	4.8		A	LIVE <3> LIVE	140	F	4.8		A
	135	F	4.3		W	LIVE <4> LIVE	141	F	4.7		W
	136	F	4.7		A	LIVE <5> LIVE	142	F	4.7		A
	137	F	4.6		W	LIVE <6> LIVE	143	F	4.7		W
FEMALE 8											
7/4	144	M	5.1		A	LIVE <1> LIVE	151	F	4.8		W
	145	M	4.9		W	LIVE <2> LIVE	152	F	5.0		A
	146	M	5.1		A	LIVE <3> LIVE	153	M	5.1		W
	147	F	4.7		W	LIVE <4> LIVE	154	F	4.7		A
	148	M	5.3		A	LIVE <5>					
	149	F	4.6		W	LIVE <6>					
	150	M	5.2		A	LIVE <7>					
FEMALE 9											
9/3	155	M	5.3		A	LIVE <1> LIVE	162	M	4.8		W
	156	F	4.3		W	LIVE <2> LIVE	163	M	4.7		A
	157	M	4.5		A	LIVE <3> LIVE	164	M	4.6		W
	158	F	4.6		W	LIVE <4> LIVE	165	M	4.7		A
	159	M	4.8		A	LIVE <5>					
	160	F	4.9		W	LIVE <6>					
	161	F	4.3		A	LIVE <7>					
FEMALE 10											
8/6	411	F	4.4		A	LIVE <1> LIVE	418	F	4.8		W
	412	F	4.7		W	LIVE <2> LIVE	419	M	4.9		A
	413	M	4.1		A	LIVE <3> E.RES					
	414	M	4.8		W	LIVE <4> LIVE	420	F	4.8		W
	415	F	5.1		A	LIVE <5> LIVE	421	M	4.5		A
	416	M	4.8		W	LIVE <6>					
	417	F	4.6		A	LIVE <7>					
FEMALE 11											
8/6	422	F	4.6		A	LIVE <1> LIVE	427	F	4.7		W
						E.RES <2> LIVE	428	M	5.2		A
	423	F	4.5		W	LIVE <3> LIVE	429	M	5.2		W
	424	F	4.9		A	LIVE <4> LIVE	430	M	5.1		A
	425	M	4.8		W	LIVE <5> LIVE	431	F	4.6		W
	426	F	4.9		A	LIVE <6>					
FEMALE 12											
8/6	432	M	4.6		A	LIVE <1> LIVE	440	M	4.8		A
	433	M	4.6		W	LIVE <2> LIVE	441	M	4.8		W
	434	F	4.3		A	LIVE <3> LIVE	442	F	4.3		A
	435	F	3.5		W	LIVE <4> LIVE	443	F	4.2		W
	436	M	4.7		A	LIVE <5> LIVE	444	M	4.6		A
	437	M	4.5		W	LIVE <6>					
	438	M	4.3		A	LIVE <7>					
	439	M	4.4		W	LIVE <8>					
FEMALE 13											
11/9	445	F	4.8		A	LIVE <1> LIVE	450	M	4.3		W
	446	F	3.9		W	LIVE <2> LIVE	451	F	4.2		A
						E.RES <3> LIVE	452	F	4.9		W
	447	F	3.9		A	LIVE <4> E.RES					
	448	M	3.9		W	LIVE <5> LIVE	453	M	4.5		A
						E.RES <6> LIVE	454	F	2.5	M	W
	449	M	5.1		A	LIVE <7>					

LIVE - LIVE FETUS E.RES - EMBRYONIC RESORPTION W - WILSON SLICING TECHNIQUE
DEAD - DEAD FETUS F.RES - FETAL RESORPTION A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 1 (0 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/ W	IMPLANTATION SITES <POS. IN UTERUS>	FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/ W
FEMALE 14											
7/8	455	F	5.2		A	LIVE <1> LIVE	460	F	4.8		W
	456	M	5.3		W	LIVE <2> LIVE	461	F	5.0		A
	457	M	5.2		A	LIVE <3> LIVE	462	M	4.9		W
	458	M	5.0		W	LIVE <4> LIVE	463	F	4.7		A
						E.RES <5> LIVE	464	M	5.1		W
	459	F	4.5		A	LIVE <6> LIVE	465	F	5.0		A
						<7> LIVE	466	M	4.9		W
FEMALE 15											
7/6	467	M	4.9		A	LIVE <1> LIVE	472	F	5.5		W
	468	M	5.6		W	LIVE <2> LIVE	473	F	5.2		A
	469	F	5.2		A	LIVE <3> LIVE	474	M	5.8		W
	470	F	5.5		W	LIVE <4> LIVE	475	M	5.8		A
						E.RES <5> LIVE	476	F	5.1		W
						E.RES <6> LIVE	477	M	5.4		A
	471	M	5.1		A	LIVE <7>					
FEMALE 16											
8/5	478	F	4.6		A	LIVE <1> LIVE	486	M	5.1		A
	479	M	4.9		W	LIVE <2> LIVE	487	M	5.1		W
	480	M	5.0		A	LIVE <3> LIVE	488	M	4.9		A
	481	M	4.8		W	LIVE <4> LIVE	489	F	4.8		W
	482	M	5.0		A	LIVE <5> LIVE	490	M	5.1		A
	483	F	4.9		W	LIVE <6>					
	484	F	4.9		A	LIVE <7>					
	485	F	4.3		W	LIVE <8>					
FEMALE 17											
8/7	491	M	4.8		A	LIVE <1> LIVE	498	F	4.3		W
	492	M	4.4		W	LIVE <2> LIVE	499	F	4.4		A
	493	F	4.2		A	LIVE <3> LIVE	500	F	4.3		W
	494	F	4.6		W	LIVE <4> LIVE	501	F	4.0		A
	495	M	4.6		A	LIVE <5> LIVE	502	F	4.6		W
	496	F	4.4		W	LIVE <6> LIVE	503	F	4.2		A
	497	M	4.6		A	LIVE <7> LIVE	504	F	4.3		W
FEMALE 18											
5/9	757	F	4.6		A	LIVE <1> LIVE	761	M	5.2		A
	758	M	4.9		W	LIVE <2> LIVE	762	F	4.5		W
	759	F	4.8		A	LIVE <3> E.RES					
	760	M	5.1		W	LIVE <4> LIVE	763	F	4.4		A
						<5> LIVE	764	F	4.1		W
						<6> F.RES					
						<7> LIVE	765	F	3.7		A
						<8> LIVE	766	F	4.5		W
						<9> LIVE	767	M	4.6		A
FEMALE 19											
5/7	768	M	5.7		A	LIVE <1> LIVE	772	F	5.0		A
	769	F	5.3		W	LIVE <2> LIVE	773	M	5.4		W
						E.RES <3> LIVE	774	M	5.7		A
	770	M	5.2		A	LIVE <4> LIVE	775	M	5.6		W
	771	F	4.8		W	LIVE <5>					
FEMALE 20											
8/5	776	F	5.1		A	LIVE <1> LIVE	784	F	5.3		A
	777	F	4.8		W	LIVE <2> LIVE	785	M	4.7		W
	778	F	4.9		A	LIVE <3> LIVE	786	F	5.0		A
	779	M	5.3		W	LIVE <4> LIVE	787	F	5.0		W
	780	F	4.9		A	LIVE <5> LIVE	788	F	4.7		A
	781	F	5.1		W	LIVE <6>					
	782	M	4.8		A	LIVE <7>					
	783	F	4.7		W	LIVE <8>					

LIVE - LIVE FETUS
DEAD - DEAD FETUS
E.RES - EMBRYONIC RESORPTION
F.RES - FETAL RESORPTION
W - WILSON SLICING TECHNIQUE
A - ALIZARIN RED S SKELETAL STAINING TECHN.

Confidential

Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 1 (0 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES <POS. IN UTERUS>			FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 21													
7/8	907	F	4.6		A	LIVE	<1>	LIVE	914	F	4.5		W
	908	M	4.5		W	LIVE	<2>	LIVE	915	F	4.7		A
	909	M	4.8		A	LIVE	<3>	LIVE	916	F	4.9		W
	910	F	4.8		W	LIVE	<4>	LIVE	917	M	4.9		A
	911	F	4.7		A	LIVE	<5>	LIVE	918	M	4.7		W
	912	M	4.8		W	LIVE	<6>	LIVE	919	M	4.7		A
	913	M	4.8		A	LIVE	<7>						
FEMALE 22													
8/7	920	F	4.2		A	LIVE	<1>	LIVE	927	F	4.9		W
	921	F	4.8		W	LIVE	<2>	LIVE	928	M	4.8		A
	922	F	4.5		A	LIVE	<3>	LIVE	929	F	4.3		W
	923	F	4.0		W	LIVE	<4>	E.RES					
	924	F	4.8		A	LIVE	<5>	LIVE	930	M	4.0		A
	925	F	4.7		W	LIVE	<6>	LIVE	931	M	4.8		W
	926	F	4.1		A	LIVE	<7>						
FEMALE 23													
9/3	932	M	4.6		A	LIVE	<1>	LIVE	941	F	5.3		W
	933	M	5.1		W	LIVE	<2>	LIVE	942	M	5.3		A
	934	F	4.7		A	LIVE	<3>	LIVE	943	F	5.2		W
	935	F	4.6		W	LIVE	<4>						
	936	F	4.7		A	LIVE	<5>						
	937	M	5.1		W	LIVE	<6>						
	938	M	5.0		A	LIVE	<7>						
	939	F	5.2		W	LIVE	<8>						
	940	M	4.9		A	LIVE	<9>						
FEMALE 24													
4/7	944	M	5.0		A	LIVE	<1>	LIVE	948	M	5.1		A
	945	M	5.1		W	LIVE	<2>	LIVE	949	F	4.6		W
	946	F	5.0		A	LIVE	<3>	LIVE	950	M	5.2		A
	947	M	5.0		W	LIVE	<4>	LIVE	951	F	4.8		W
							<5>	LIVE	952	M	5.1		A
							<6>	LIVE	953	F	4.6		W
FEMALE 25													
7/4	954	F	4.9		A	LIVE	<1>	LIVE	961	M	4.9		W
	955	M	4.5		W	LIVE	<2>	LIVE	962	F	4.7		A
	956	M	4.8		A	LIVE	<3>	LIVE	963	F	4.6		W
	957	F	4.5		W	LIVE	<4>	LIVE	964	M	4.6		A
	958	M	5.0		A	LIVE	<5>						
	959	M	4.8		W	LIVE	<6>						
	960	M	4.4		A	LIVE	<7>						

LIVE - LIVE FETUS E.RES - EMBRYONIC RESORPTION W - WILSON SLICING TECHNIQUE
DEAD - DEAD FETUS F.RES - FETAL RESORPTION A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 2 (10 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES <POS. IN UTERUS>	FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 26											
9/5	65	M	5.7		A	LIVE <1> LIVE	73	F	5.0		A
	66	M	5.6		W	LIVE <2> LIVE	74	M	5.4		W
	67	F	5.3		A	LIVE <3> LIVE	75	F	5.3		A
	68	F	5.4		W	LIVE <4> LIVE	76	M	5.3		W
	69	F	5.4		A	LIVE <5> LIVE	77	M	5.3		A
	70	F	4.9		W	LIVE <6>					
	71	M	5.3		A	LIVE <7>					
						E.RES <8>					
	72	M	5.2		W	LIVE <9>					
FEMALE 27											
4/11	78	F	5.1		A	LIVE <1> LIVE	81	M	5.0		W
	79	M	5.2		W	LIVE <2> LIVE	82	M	5.0		A
	80	M	5.0		A	LIVE <3> LIVE	83	F	4.2		W
						<4> LIVE	84	F	4.4		A
						<5> LIVE	85	F	4.6		W
						<6> LIVE	86	M	4.9		A
						<7> LIVE	87	F	4.4		W
						<8> LIVE	88	F	4.8		A
						<9> LIVE	89	M	5.0		W
						<10> LIVE	90	F	4.4		A
FEMALE 28											
7/1	166	M	6.0		A	LIVE <1>					
FEMALE 29											
5/7	167	M	5.2		A	LIVE <1> LIVE	169	M	4.8		A
	168	M	5.3		W	LIVE <2> LIVE	170	F	5.0		W
						E.RES <3> LIVE	171	F	4.9		A
						E.RES <4> LIVE	172	M	5.0		W
						<5> LIVE	173	F	4.8		A
						<6> LIVE	174	M	5.3		W
FEMALE 30	(Non-Pregnant)										
FEMALE 31											
5/9	175	M	4.6		A	LIVE <1> LIVE	179	M	4.8		A
						E.RES <2> LIVE	180	F	4.4		W
	176	F	4.4		W	LIVE <3> LIVE	181	M	4.9		A
	177	F	4.3		A	LIVE <4> LIVE	182	F	4.6		W
	178	M	4.7		W	LIVE <5> E.RES					
						<6> LIVE	183	M	4.1		A
						<7> LIVE	184	F	4.5		W
						<8> LIVE	185	F	4.4		A
FEMALE 32											
6/8	186	F	5.2		A	LIVE <1> LIVE	190	F	5.4		A
	187	F	5.5		W	LIVE <2> E.RES					
	188	F	5.4		A	LIVE <3> LIVE	191	M	5.8		W
	189	M	5.2		W	LIVE <4> LIVE	192	F	5.3		A
						<5> LIVE	193	F	5.7		W
						<6> LIVE	194	F	5.0		A

LIVE - LIVE FETUS
DEAD - DEAD FETUS
E.RES - EMBRYONIC RESORPTION
F.RES - FETAL RESORPTION
W - WILSON SLICING TECHNIQUE
A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 2 (10 MG/KG)

Confidential

Copyright by Bayer AG
the use, utilization or distribution
is only permitted with the consent
of Bayer AG.

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES (POS. IN UTERUS)			FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 33													
11/5	195	M	4.9		A	LIVE	<1>	LIVE	204	M	5.1		W
	196	F	4.6		W	LIVE	<2>	E.RES					
	197	M	4.6		A	LIVE	<3>	LIVE	205	F	4.8		A
	198	F	4.9		W	LIVE	<4>	LIVE	206	M	4.8		W
	199	M	5.1		A	LIVE	<5>						
	200	F	4.5		W	LIVE	<6>						
	201	M	4.9		A	LIVE	<7>						
	202	F	4.6		W	LIVE	<8>						
	203	F	4.7		A	LIVE	<9>						
FEMALE 34													
8/7	207	M	4.6		A	LIVE	<1>	LIVE	214	F	5.1		W
	208	M	4.9		W	LIVE	<2>	LIVE	215	M	4.9		A
	209	M	5.2		A	LIVE	<3>	LIVE	216	M	5.0		W
	210	F	4.9		W	LIVE	<4>	LIVE	217	M	4.8		A
	211	F	4.8		A	LIVE	<5>						
	212	F	4.8		W	LIVE	<6>						
	213	M	4.7		A	LIVE	<7>						
						E.RES	<8>						
FEMALE 35													
8/5	218	F	5.0		A	LIVE	<1>	LIVE	225	F	5.2		W
	219	F	5.2		W	LIVE	<2>	LIVE	226	F	5.0		A
	220	M	5.3		A	LIVE	<3>	LIVE	227	F	5.0		W
						E.RES	<4>	LIVE	228	F	4.9		A
	221	M	4.8		W	LIVE	<5>	LIVE	229	F	4.1		W
	222	F	4.3		A	LIVE	<6>						
	223	F	4.8		W	LIVE	<7>						
	224	F	4.1		A	LIVE	<8>						
FEMALE 36													
4/9	230	F	4.6		A	LIVE	<1>	LIVE	233	F	4.8		W
	231	M	5.2		W	LIVE	<2>	LIVE	234	F	5.0		A
	232	M	5.3		A	LIVE	<3>	LIVE	235	M	4.4		W
							<4>	LIVE	236	F	4.8		A
							<5>	LIVE	237	F	4.0		W
							<6>	LIVE	238	F	4.8		A
							<7>	LIVE	239	F	4.9		W
							<8>	LIVE	240	M	4.8		A
							<9>	LIVE	241	M	3.0		W
FEMALE 37													
5/9	242	M	5.1		A	LIVE	<1>	LIVE	246	M	5.0		A
	243	M	5.3		W	LIVE	<2>	LIVE	247	F	4.9		W
	244	F	5.1		A	LIVE	<3>	LIVE	248	F	4.8		A
	245	F	4.5		W	LIVE	<4>	LIVE	249	M	5.0		W
							<5>	LIVE	250	F	5.0		A
							<6>	LIVE	251	M	5.0		W
							<7>	LIVE	252	F	5.1		A
							<8>	LIVE	253	M	5.0		W
FEMALE 38													
7/7	254	M	5.7		A	LIVE	<1>	LIVE	260	F	5.0		A
	255	F	5.0		W	LIVE	<2>	LIVE	261	M	5.2		W
	256	F	5.3		A	LIVE	<3>	LIVE	262	M	4.9		A
	257	F	4.8		W	LIVE	<4>	LIVE	263	M	5.2		W
	258	F	5.1		A	LIVE	<5>	LIVE	264	M	5.7		A
	259	F	4.8		W	LIVE	<6>	LIVE	265	M	5.2		W
							<7>	LIVE	266	M	5.1		A

LIVE - LIVE FETUS E.RES - EMBRYONIC RESORPTION W - WILSON SLICING TECHNIQUE
DEAD - DEAD FETUS F.RES - FETAL RESORPTION A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 2 (10 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES (POS. IN UTERUS)			FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 39													
7/7	505	F	4.6		A	LIVE	<1>	LIVE	511	M	5.4		A
	506	F	4.8		W	LIVE	<2>	LIVE	512	M	5.1		W
	507	F	5.1		A	LIVE	<3>	LIVE	513	M	5.3		A
	508	F	4.8		W	LIVE	<4>	LIVE	514	M	4.8		W
	509	M	5.6		A	LIVE	<5>	LIVE	515	F	3.2		A
	510	F	4.9		W	LIVE	<6>	LIVE	516	F	5.0		W
							<7>	LIVE	517	M	5.1		A
FEMALE 40													
6/7	518	M	4.8		A	LIVE	<1>	LIVE	524	M	5.1		A
	519	M	4.9		W	LIVE	<2>	LIVE	525	M	4.9		W
	520	M	4.8		A	LIVE	<3>	LIVE	526	F	5.1		A
	521	F	5.0		W	LIVE	<4>	LIVE	527	F	4.6		W
	522	F	4.7		A	LIVE	<5>	LIVE	528	F	4.8		A
	523	M	4.8		W	LIVE	<6>	LIVE	529	M	5.2		W
							<7>	LIVE	530	F	4.3		A
FEMALE 41													
7/6	531	F	4.5		A	LIVE	<1>	LIVE	537	M	4.3		A
	532	M	4.8		W	LIVE	<2>	LIVE	538	M	4.9		W
	533	F	4.6		A	LIVE	<3>	LIVE	539	M	5.0		A
	534	M	4.3		W	LIVE	<4>	LIVE	540	M	4.7		W
	535	M	4.5		A	LIVE	<5>	LIVE	541	M	4.7		A
	536	F	3.8		W	LIVE	<6>	LIVE	542	M	4.7		W
FEMALE 42													
7/7	543	F	4.4		A	LIVE	<1>	LIVE	548	M	5.1		W
	544	M	5.2		W	LIVE	<2>	LIVE	549	F	4.4		A
	545	M	5.2		A	LIVE	<3>	LIVE	550	M	5.0		W
	546	M	5.2		W	LIVE	<4>	LIVE	551	M	5.2		A
						E.RES	<5>	LIVE	552	M	4.7		W
						E.RES	<6>	E.RES					
	547	M	4.7		A	LIVE	<7>						
FEMALE 43													
6/7	553	M	4.9		A	LIVE	<1>	LIVE	559	F	4.8		A
	554	M	4.4		W	LIVE	<2>	LIVE	560	F	4.1		W
	555	F	4.9		A	LIVE	<3>	LIVE	561	M	4.9		A
	556	F	5.0		W	LIVE	<4>	LIVE	562	M	4.8		W
	557	M	5.1		A	LIVE	<5>	LIVE	563	M	5.1		A
	558	M	4.6		W	LIVE	<6>						
FEMALE 44													
8/7	564	F	5.2		A	LIVE	<1>	LIVE	571	F	5.5		W
	565	M	5.8		W	LIVE	<2>	LIVE	572	F	5.3		A
	566	F	5.1		A	LIVE	<3>	LIVE	573	M	5.9		W
	567	F	5.5		W	LIVE	<4>	LIVE	574	F	5.0		A
						E.RES	<5>	LIVE	575	M	5.4		W
	568	F	5.3		A	LIVE	<6>	LIVE	576	M	5.2		A
	569	F	5.1		W	LIVE	<7>	LIVE	577	M	5.6		W
	570	M	5.0		A	LIVE	<8>						

FEMALE 45 (Non-Pregnant)

LIVE - LIVE FETUS
DEAD - DEAD FETUS
E.RES - EMBRYONIC RESORPTION
F.RES - FETAL RESORPTION
W - WILSON SLICING TECHNIQUE
A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 2 (10 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES (POS. IN UTERUS)	FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 46											
4/11						E.RES <1> LIVE	791	F	4.6		A
	789	M	4.7		A	LIVE <2> LIVE	792	M	4.4		W
						E.RES <3> LIVE	793	M	5.0		A
	790	F	4.7		W	LIVE <4> LIVE	794	M	4.6		W
						<5> LIVE	795	F	4.4		A
						<6> LIVE	796	F	4.7		W
						<7> LIVE	797	M	4.6		A
						<8> LIVE	798	M	4.8		W
						<9> LIVE	799	M	4.5		A
						<10> LIVE	800	M	4.8		W
						<11> LIVE	801	F	4.3		A
FEMALE 47											
8/6	802	F	4.5		A	LIVE <1> LIVE	810	F	4.5		A
	803	F	3.7		W	LIVE <2> LIVE	811	M	4.6		W
	804	M	4.3		A	LIVE <3> LIVE	812	F	4.5		A
	805	F	4.2		W	LIVE <4> LIVE	813	M	4.8		W
	806	M	4.3		A	LIVE <5> LIVE	814	M	4.5		A
	807	M	4.7		W	LIVE <6> LIVE	815	M	4.9		W
	808	M	4.4		A	LIVE <7>					
	809	M	4.4		W	LIVE <8>					
FEMALE 48											
5/9	965	M	5.0		A	LIVE <1> E.RES					
	966	M	4.4		W	LIVE <2> LIVE	970	M	5.4		W
	967	F	4.9		A	LIVE <3> LIVE	971	F	4.8		A
	968	M	4.9		W	LIVE <4> LIVE	972	M	5.0		W
	969	F	5.1		A	LIVE <5> LIVE	973	F	4.5		A
						<6> LIVE	974	M	4.9		W
						<7> LIVE	975	M	4.7		A
						<8> LIVE	976	M	5.0		W
						<9> LIVE	977	M	4.3		A
FEMALE 49											
8/5	978	F	4.7		A	LIVE <1> LIVE	986	F	4.9		A
	979	F	4.7		W	LIVE <2> LIVE	987	M	5.7		W
	980	M	5.0		A	LIVE <3> LIVE	988	M	4.9		A
	981	M	4.5		W	LIVE <4> E.RES					
	982	F	4.2		A	LIVE <5>					
	983	M	4.6		W	LIVE <6>					
	984	M	5.0		A	LIVE <7>					
	985	F	4.2		W	LIVE <8>					
FEMALE 50											
5/8	989	M	5.2		A	LIVE <1> LIVE	993	M	5.2		A
	990	F	4.9		W	LIVE <2> LIVE	994	M	4.8		W
	991	F	5.0		A	LIVE <3> LIVE	995	F	4.8		A
	992	F	4.2		W	LIVE <4> LIVE	996	F	5.0		W
						<5> LIVE	997	M	5.1		A

LIVE - LIVE FETUS E.RES - EMBRYONIC RESORPTION W - WILSON SLICING TECHNIQUE
DEAD - DEAD FETUS F.RES - FETAL RESORPTION A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 3 (30 MG/KG)

Confidential
Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES (POS. IN UTERUS)			FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 51													
7/8	91	F	5.4		A	LIVE	<1>	LIVE	95	F	4.9		A
						E.RES	<2>	LIVE	96	F	4.8		W
	92	M	5.3		W	LIVE	<3>	LIVE	97	F	2.3	M	A
	93	M	5.4		A	LIVE	<4>	LIVE	98	F	4.9		W
						E.RES	<5>	LIVE	99	M	3.8		A
	94	M	5.7		W	LIVE	<6>	LIVE	100	F	4.7		W
							<7>	LIVE	101	F	5.0		A
FEMALE 52													
7/6	267	M	5.3		A	LIVE	<1>	LIVE	273	M	5.3		A
	268	M	4.9		W	LIVE	<2>	LIVE	274	F	4.9		W
	269	F	5.0		A	LIVE	<3>	LIVE	275	F	4.4		A
	270	M	4.8		W	LIVE	<4>	LIVE	276	F	5.1		W
	271	F	4.9		A	LIVE	<5>	LIVE	277	F	5.0		A
	272	F	4.7		W	LIVE	<6>						
FEMALE 53													
7/8	278	M	5.2		A	LIVE	<1>	LIVE	284	M	5.2		A
	279	F	4.5		W	LIVE	<2>	LIVE	285	M	4.8		W
						E.RES	<3>	LIVE	286	M	5.2		A
	280	M	4.6		A	LIVE	<4>	LIVE	287	M	4.3		W
	281	M	4.8		W	LIVE	<5>	E.RES					
	282	F	4.1		A	LIVE	<6>	LIVE	288	M	4.8		A
	283	F	4.7		W	LIVE	<7>						
FEMALE 54													
7/5	289	F	4.4		A	LIVE	<1>	LIVE	295	F	4.6		A
						E.RES	<2>	LIVE	296	M	4.7		W
	290	F	4.1		W	LIVE	<3>	LIVE	297	F	5.0		A
	291	M	5.1		A	LIVE	<4>	LIVE	298	F	4.6		W
	292	F	4.6		W	LIVE	<5>	LIVE	299	M	4.9		A
	293	M	4.3		A	LIVE	<6>						
	294	M	4.9		W	LIVE	<7>						
FEMALE 55													
9/7	300	F	4.2		A	LIVE	<1>	LIVE	309	F	5.2		W
	301	M	5.0		W	LIVE	<2>	LIVE	310	M	4.8		A
	302	F	4.8		A	LIVE	<3>	LIVE	311	F	4.9		W
	303	F	4.3		W	LIVE	<4>	LIVE	312	F	5.0		A
	304	M	5.2		A	LIVE	<5>	LIVE	313	F	4.4		W
	305	F	4.7		W	LIVE	<6>	LIVE	314	M	4.9		A
	306	M	5.1		A	LIVE	<7>						
	307	F	4.9		W	LIVE	<8>						
	308	F	4.0		A	LIVE	<9>						
FEMALE 56													
5/8	315	F	4.5		A	LIVE	<1>	LIVE	319	M	5.2		A
	316	M	5.4		W	LIVE	<2>	LIVE	320	F	4.7		W
	317	F	4.8		A	LIVE	<3>	LIVE	321	F	5.1		A
	318	M	5.1		W	LIVE	<4>	LIVE	322	F	5.0		W
							<5>	LIVE	323	F	4.1		A
							<6>	LIVE	324	F	4.7		W
							<7>	LIVE	325	M	4.9		A
FEMALE 57													
9/7	578	M	5.2		A	LIVE	<1>	LIVE	586	M	4.9		A
	579	M	5.2		W	LIVE	<2>	LIVE	587	F	4.5		W
	580	F	4.8		A	LIVE	<3>	LIVE	588	M	4.7		A
	581	F	4.6		W	LIVE	<4>	E.RES					
	582	F	4.7		A	LIVE	<5>	LIVE	589	F	4.8		W
	583	M	5.0		W	LIVE	<6>	LIVE	590	M	5.2		A
	584	M	4.4		A	LIVE	<7>						
	585	M	4.9		W	LIVE	<8>						

LIVE - LIVE FETUS E.RES - EMBRYONIC RESORPTION W - WILSON SLICING TECHNIQUE
DEAD - DEAD FETUS F.RES - FETAL RESORPTION A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 3 (30 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES <POS. IN UTERUS>	FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 58											
5/8	591	M	4.7		A	LIVE <1> LIVE	596	F	4.2		W
	592	M	4.5		W	LIVE <2> LIVE	597	M	4.6		A
	593	M	4.4		A	LIVE <3> LIVE	598	F	5.0		W
	594	F	4.3		W	LIVE <4> LIVE	599	F	4.2		A
	595	M	4.0		A	LIVE <5> LIVE	600	F	4.3		W
						<6> LIVE	601	M	4.6		A
FEMALE 59											
9/7	602	M	5.1		A	LIVE <1> LIVE	610	M	5.2		A
	603	F	4.8		W	LIVE <2> LIVE	611	F	4.4		W
	604	M	5.0		A	LIVE <3> LIVE	612	M	5.2		A
	605	F	4.8		W	LIVE <4> LIVE	613	F	4.8		W
	606	M	5.3		A	LIVE <5> LIVE	614	M	4.8		A
	607	M	4.8		W	LIVE <6> LIVE	615	M	4.8		W
	608	F	4.5		A	LIVE <7>					
	609	F	4.5		W	LIVE <8>					
FEMALE 60											
4/10	616	M	5.7		A	LIVE <1> LIVE	618	F	5.3		A
						E.RES <2> E.RES					
	617	F	4.5		W	LIVE <3> LIVE	619	M	5.4		W
						<4> LIVE	620	M	5.7		A
						<5> LIVE	621	M	4.7		W
						<6> LIVE	622	F	4.5		A
						<7> LIVE	623	F	5.1		W
						<8> LIVE	624	F	4.7		A
						<9> LIVE	625	M	4.7		W
FEMALE 61											
2/7	626	F	5.0		A	LIVE <1> LIVE	628	M	5.2		A
	627	F	5.0		W	LIVE <2> LIVE	629	F	4.8		W
						<3> LIVE	630	F	5.2		A
						<4> LIVE	631	M	5.3		W
						<5> LIVE	632	F	5.2		A
						<6> LIVE	633	M	4.9		W
						<7> LIVE	634	F	5.0		A
FEMALE 62											
8/6	635	M	5.1		A	LIVE <1> LIVE	643	M	5.6		A
	636	M	5.3		W	LIVE <2> LIVE	644	M	5.5		W
	637	F	5.1		A	LIVE <3> LIVE	645	M	5.0		A
	638	F	5.0		W	LIVE <4> LIVE	646	F	4.7		W
	639	M	5.5		A	LIVE <5> LIVE	647	F	4.2		A
	640	F	4.7		W	LIVE <6> E.RES					
	641	M	4.9		A	LIVE <7>					
	642	F	3.9		W	LIVE <8>					
FEMALE 63											
4/8	648	F	5.4		A	LIVE <1> LIVE	650	F	5.1		A
	649	M	5.6		W	LIVE <2> LIVE	651	M	5.3		W
						<3> LIVE	652	M	5.7		A
						<4> LIVE	653	F	5.5		W
						<5> LIVE	654	M	5.6		A
						<6> E.RES					
						<7> LIVE	655	F	4.9		W
						<8> LIVE	656	M	5.0		A

LIVE - LIVE FETUS E.RES - EMBRYONIC RESORPTION W - WILSON SLICING TECHNIQUE
DEAD - DEAD FETUS F.RES - FETAL RESORPTION A - ALIZARIN RED S SKELETAL STAINING TECHN.

Confidential

Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 3 (30 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES (POS. IN UTERUS)	FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 64											
7/4	657	M	5.0		A	LIVE <1> LIVE	663	M	5.4		A
	658	F	5.2		W	LIVE <2> LIVE	664	F	5.1		W
	659	F	5.1		A	LIVE <3> LIVE	665	M	5.6		A
	660	F	5.3		W	LIVE <4> LIVE	666	F	4.8		W
						E.RES <5>					
	661	M	4.6		A	LIVE <6>					
	662	M	5.0		W	LIVE <7>					
FEMALE 65											
8/5	667	F	5.0		A	LIVE <1> LIVE	674	F	5.1		W
	668	F	5.1		W	LIVE <2> LIVE	675	M	5.8		A
	669	M	5.8		A	LIVE <3> LIVE	676	F	4.8		W
	670	M	5.7		W	LIVE <4> LIVE	677	M	5.4		A
	671	F	5.1		A	LIVE <5> LIVE	678	M	5.7		W
	672	F	5.2		W	LIVE <6>					
	673	F	5.2		A	LIVE <7>					
FEMALE 66											
6/6	679	M	5.4		A	LIVE <1> LIVE	684	F	5.0		W
	680	F	4.6		W	LIVE <2> LIVE	685	M	5.0		A
	681	F	5.0		A	LIVE <3> LIVE	686	M	5.3		W
	682	F	4.8		W	LIVE <4> LIVE	687	M	5.4		A
	683	F	5.0		A	LIVE <5> LIVE	688	M	5.1		W
FEMALE 67											
7/7	689	F	4.4		A	LIVE <1> LIVE	695	F	4.9		A
	690	F	4.4		W	LIVE <2> LIVE	696	M	4.9		W
	691	F	4.7		A	LIVE <3> LIVE	697	F	4.1		A
	692	M	4.4		W	LIVE <4> LIVE	698	F	4.5		W
	693	M	4.6		A	LIVE <5> LIVE	699	M	4.9		A
	694	F	4.5		W	LIVE <6>					
FEMALE 68											
8/7	700	M	4.9		A	LIVE <1> LIVE	705	F	4.5		W
						E.RES <2> LIVE	706	M	5.4		A
	701	F	5.0		W	LIVE <3> LIVE	707	M	5.3		W
						E.RES <4> LIVE	708	F	5.0		A
	702	F	4.9		A	LIVE <5> LIVE	709	F	4.9		W
	703	F	4.7		W	LIVE <6> LIVE	710	M	5.4		A
	704	F	4.1		A	LIVE <7> LIVE	711	M	5.1		W
FEMALE 69	(Non-Pregnant)										
FEMALE 70											
9/3	816	M	5.5		A	LIVE <1> LIVE	824	M	5.2		A
	817	M	5.5		W	LIVE <2> LIVE	825	F	4.9		W
						E.RES <3> LIVE	826	F	4.7		A
	818	M	5.2		A	LIVE <4>					
	819	M	5.5		W	LIVE <5>					
	820	F	4.9		A	LIVE <6>					
	821	M	5.2		W	LIVE <7>					
	822	F	4.8		A	LIVE <8>					
	823	M	5.5		W	LIVE <9>					

LIVE - LIVE FETUS
DEAD - DEAD FETUS
E.RES - EMBRYONIC RESORPTION
F.RES - FETAL RESORPTION
W - WILSON SLICING TECHNIQUE
A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 3 (30 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES <POS. IN UTERUS>	FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 71											
8/6	827	M	5.6		A	LIVE <1> LIVE	834	F	5.2		W
	828	F	5.2		W	LIVE <2> LIVE	835	M	5.7		A
	829	F	5.3		A	LIVE <3> LIVE	836	F	5.3		W
	830	M	5.2		W	LIVE <4> LIVE	837	F	5.1		A
						E.RES <5> LIVE	838	F	5.0		W
	831	M	5.6		A	LIVE <6> LIVE	839	F	4.8		A
	832	M	5.3		W	LIVE <7>					
	833	M	5.0		A	LIVE <8>					
FEMALE 72											
7/5	856	F	5.0		A	LIVE <1> LIVE	861	F	5.3		W
	857	M	5.5		W	LIVE <2> LIVE	862	F	5.3		A
	858	F	5.3		A	LIVE <3> LIVE	863	M	5.5		W
						E.RES <4> LIVE	864	F	5.0		A
	859	M	5.5		W	LIVE <5>					
						E.RES <6>					
	860	M	5.2		A	LIVE <7>					
FEMALE 73											
11/2	998	M	3.0		A	LIVE <1> LIVE	1006	F	4.9		A
	999	F	4.6		W	LIVE <2> LIVE	1007	M	5.2		W
						E.RES <3>					
	1000	F	4.8		A	LIVE <4>					
	1001	M	4.5		W	LIVE <5>					
	1002	M	3.2		A	LIVE <6>					
	1003	M	4.8		W	LIVE <7>					
						E.RES <8>					
						F.RES <9>					
	1004	M	4.5		A	LIVE <10>					
	1005	F	4.5		W	LIVE <11>					
FEMALE 74											
12/3	1008	F	5.1		A	LIVE <1> E.RES					
	1009	F	5.0		W	LIVE <2> LIVE	1019	M	5.1		W
	1010	F	4.8		A	LIVE <3> LIVE	1020	M	5.0		A
	1011	M	4.6		W	LIVE <4>					
	1012	M	5.0		A	LIVE <5>					
	1013	F	4.5		W	LIVE <6>					
	1014	F	4.8		A	LIVE <7>					
						E.RES <8>					
	1015	F	5.1		W	LIVE <9>					
	1016	F	5.0		A	LIVE <10>					
	1017	F	4.8		W	LIVE <11>					
	1018	M	5.1		A	LIVE <12>					
FEMALE 75											
7/5	1021	F	4.8		A	LIVE <1> LIVE	1028	F	4.6		W
	1022	F	4.5		W	LIVE <2> LIVE	1029	F	4.6		A
	1023	F	4.5		A	LIVE <3> E.RES					
	1024	M	4.8		W	LIVE <4> LIVE	1030	M	4.9		W
	1025	M	4.8		A	LIVE <5> LIVE	1031	F	4.4		A
	1026	M	4.5		W	LIVE <6>					
	1027	F	4.3		A	LIVE <7>					

LIVE - LIVE FETUS E.RES - EMBRYONIC RESORPTION W - WILSON SLICING TECHNIQUE
DEAD - DEAD FETUS F.RES - FETAL RESORPTION A - ALIZARIN RED S SKELETAL STAINING TECHN.

RCC PROJECT 236114
SXX 0665 TECHNICAL

CAE-UT - 1
25-APR-9

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 4 (100 MG/KG)

Confidential

Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. A/ MALF. W	IMPLANTATION SITES (POS. IN UTERUS)	FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. A/ MALF.
FEMALE 76									
9/10	102	F	4.8	A	LIVE <1> F.RES				
	103	F	4.6	W	LIVE <2> E.RES				
	104	F	4.8	A	LIVE <3> E.RES				
	105	F	4.7	W	LIVE <4> E.RES				
	106	F	4.4	A	E.RES <5>				
					LIVE <6>				
FEMALE 77									
8/7	107	M	5.3	A	LIVE <1> LIVE	114	F	5.0	W
	108	M	5.0	W	LIVE <2> LIVE	115	F	4.6	A
	109	M	5.0	A	LIVE <3> LIVE	116	F	5.0	W
	110	F	5.0	W	LIVE <4> LIVE	117	F	4.2	A
	111	F	4.7	A	LIVE <5> LIVE	118	F	5.0	W
	112	F	4.9	W	LIVE <6>				
	113	F	4.8	A	LIVE <7>				
FEMALE 78									
10/5	326	F	5.2	A	LIVE <1> LIVE	335	M	5.6	W
	327	M	4.0	W	LIVE <2> E.RES				
	328	M	5.4	A	LIVE <3> LIVE	336	F	4.3	M W
	329	M	5.0	W	LIVE <4>				
	330	F	4.9	A	LIVE <5>				
	331	F	5.2	W	LIVE <6>				
	332	F	5.2	A	LIVE <7>				
	333	F	5.2	W	LIVE <8>				
	334	F	5.1	A	LIVE <9>				
FEMALE 79									
6/9	337	F	4.2	A	LIVE <1> LIVE	340	F	4.4	W
	338	M	4.5	W	LIVE <2> LIVE	341	F	4.3	A
					F.RES <3> LIVE	342	F	4.0	W
	339	M	4.8	A	F.RES <4> LIVE	343	M	3.4	A
					LIVE <5> LIVE	344	F	3.5	W
					<6> LIVE	345	M	4.1	A
					<7> LIVE	346	F	4.8	W
					<8> LIVE	347	M	4.9	A
FEMALE 80									
7/6	348	M	4.4	A	LIVE <1> LIVE	355	F	4.7	W
	349	F	4.9	W	LIVE <2> LIVE	356	M	5.0	A
	350	F	4.4	A	LIVE <3> LIVE	357	F	5.2	W
	351	M	5.3	W	LIVE <4> LIVE	358	M	5.3	A
	352	M	5.2	A	LIVE <5> LIVE	359	F	4.5	W
	353	F	4.7	W	LIVE <6> LIVE	360	F	5.2	A
	354	M	4.6	A	LIVE <7>				
FEMALE 81									
7/6	361	M	4.8	A	LIVE <1> LIVE	368	M	5.1	W
	362	F	4.8	W	LIVE <2> LIVE	369	F	5.0	A
	363	M	4.9	A	LIVE <3> LIVE	370	F	5.0	W
	364	F	4.8	W	LIVE <4> LIVE	371	M	5.2	A
	365	F	5.2	A	LIVE <5> LIVE	372	F	5.0	W
	366	M	5.3	W	LIVE <6>				
	367	F	4.9	A	LIVE <7>				

LIVE - LIVE FETUS
DEAD - DEAD FETUS

E.RES - EMBRYONIC RESORPTION
F.RES - FETAL RESORPTION

W - WILSON SLICING TECHNIQUE
A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 4 (100 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/ W	IMPLANTATION SITES <POS. IN UTERUS>	FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/ W
FEMALE 82											
8/7						F.RES <1> LIVE	377	M	4.3		A
	373	M	4.1		A	LIVE <2> LIVE	378	M	4.3		W
	374	F	4.4		W	LIVE <3> LIVE	379	F	3.8		A
						F.RES <4> LIVE	380	F	4.3		W
						E.RES <5> E.RES					
	375	F	3.1		A	LIVE <6> LIVE	381	M	4.1		A
						E.RES <7>					
	376	M	4.2		W	LIVE <8>					
FEMALE 83											
7/6	382	M	4.0		A	LIVE <1> LIVE	387	F	5.3		W
	383	M	5.5		W	LIVE <2> LIVE	388	M	5.0		A
	384	F	4.8		A	LIVE <3> LIVE	389	M	5.2		W
						E.RES <4> LIVE	390	F	5.1		A
	385	M	4.5		W	LIVE <5> LIVE	391	M	4.8		W
						E.RES <6>					
	386	F	4.8		A	LIVE <7>					
FEMALE 84											
2/9						E.RES <1> LIVE	392	F	5.0		A
						<2> E.RES					
						<3> E.RES					
						<4> E.RES					
FEMALE 85											
7/8	393	M	5.6		A	LIVE <1> E.RES					
	394	M	3.5		W	LIVE <2> E.RES					
						E.RES <3> LIVE	397	F	5.3		A
	395	M	5.4		A	LIVE <4> LIVE	398	M	5.1		W
	396	F	5.1		W	LIVE <5> F.RES					
						E.RES <6> LIVE	399	F	4.8		A
FEMALE 86											
9/7	400	M	5.8		A	LIVE <1> LIVE	407	F	5.1		W
	401	M	5.7		W	LIVE <2> LIVE	408	F	5.2		A
	402	M	4.2		A	LIVE <3> LIVE	409	F	5.0		W
	403	F	5.3		W	LIVE <4> E.RES					
	404	F	4.7		A	LIVE <5> LIVE	410	M	5.5		A
	405	F	5.0		W	LIVE <6> E.RES					
						E.RES <7> E.RES					
	406	M	5.5		A	LIVE <8>					
FEMALE 87											
8/7						E.RES <1> LIVE	718	M	5.4		A
	712	M	4.7		A	LIVE <2> LIVE	719	F	4.5		W
	713	M	4.7		W	LIVE <3> LIVE	720	F	4.7		A
	714	F	4.4		A	LIVE <4> LIVE	721	M	4.5		W
						E.RES <5> LIVE	722	M	5.1		A
	715	M	4.6		W	LIVE <6> LIVE	723	F	4.7		W
	716	M	4.2		A	LIVE <7>					
	717	M	4.5		W	LIVE <8>					
FEMALE 88											
9/4						F.RES <1> LIVE	731	M	5.5		W
	724	F	4.2	M	A	LIVE <2> LIVE	732	M	5.6		A
	725	M	5.8		W	LIVE <3> LIVE	733	F	5.1		W
	726	F	4.3		A	LIVE <4> LIVE	734	M	5.4		A
	727	M	5.5		W	LIVE <5>					
	728	F	5.1		A	LIVE <6>					
	729	M	5.8		W	LIVE <7>					
						E.RES <8>					
	730	F	4.7		A	LIVE <9>					

LIVE - LIVE FETUS E.RES - EMBRYONIC RESORPTION W - WILSON SLICING TECHNIQUE
DEAD - DEAD FETUS F.RES - FETAL RESORPTION A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 4 (100 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W	IMPLANTATION SITES (POS. IN UTERUS)	FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/W
FEMALE 89 4/5	735	F	5.8		A	LIVE <1> LIVE	737	F	5.6		A
	736	F	4.9		W	LIVE <2> LIVE	738	M	5.8		W
						<3> LIVE	739	M	5.4		A
FEMALE 90	(Non-Pregnant)										
FEMALE 91 8/6	740	F	4.2		A	LIVE <1> LIVE	746	M	4.7		A
	741	M	5.1		W	LIVE <2> LIVE	747	F	4.9		W
	742	F	4.1		A	LIVE <3> E.RES	748	M	4.7		A
	743	M	4.4		W	LIVE <4> LIVE					
	744	F	4.3		A	LIVE <5> E.RES					
	745	M	4.2		W	E.RES <6> E.RES					
						LIVE <7>					
						E.RES <8>					
FEMALE 92 7/7	749	M	5.4		A	F.RES <1> E.RES	753	F	4.7		A
	750	M	4.5		W	LIVE <2> E.RES	754	M	4.6		W
	751	F	4.1		A	LIVE <3> LIVE	755	F	5.1		A
	752	F	3.9		W	F.RES <4> LIVE	756	F	4.4		W
						LIVE <5> LIVE					
						LIVE <6> F.RES					
						<7> LIVE					
FEMALE 93 8/8	840	M	4.7		A	LIVE <1> LIVE	848	F	4.1		A
	841	M	4.6		W	LIVE <2> LIVE	849	F	4.7		W
	842	F	4.5		A	LIVE <3> LIVE	850	M	4.9		A
	843	M	4.8		W	LIVE <4> LIVE	851	F	4.4		W
	844	F	4.6		A	LIVE <5> LIVE	852	M	4.6		A
	845	M	4.3		W	LIVE <6> LIVE	853	F	4.6		W
	846	M	4.9		A	LIVE <7> LIVE	854	M	4.6		A
	847	F	4.4		W	LIVE <8> LIVE	855	F	4.6		W
FEMALE 94 7/6	863	M	5.0		A	LIVE <1> LIVE	872	M	4.6		W
	866	F	4.7		W	LIVE <2> LIVE	873	F	4.3		A
	867	M	4.3		A	LIVE <3> LIVE	874	F	4.9		W
	868	M	4.6		W	LIVE <4> LIVE	875	M	4.1		A
	869	F	5.0		A	LIVE <5> LIVE	876	M	4.9		W
	870	F	4.6		W	LIVE <6> E.RES					
	871	F	4.5		A	LIVE <7>					
FEMALE 95 8/7	877	F	5.1		A	LIVE <1> LIVE	885	M	5.2		A
	878	M	4.9		W	LIVE <2> LIVE	886	F	4.7		W
	879	M	4.3		A	LIVE <3> LIVE	887	M	5.2		A
	880	M	4.5		W	LIVE <4> LIVE	888	M	5.2		W
	881	M	5.1		A	LIVE <5> LIVE	889	F	5.0		A
	882	F	4.9		W	LIVE <6> LIVE	890	F	3.6		W
	883	F	3.6		A	LIVE <7>					
	884	F	4.7		W	LIVE <8>					
FEMALE 96 6/8	891	M	4.9		A	LIVE <1> LIVE	893	M	5.0		A
	892	M	4.7		W	LIVE <2> LIVE	894	F	5.1		W
						E.RES <3> LIVE	895	F	4.8		A
						<4> E.RES	896	F	4.5		W
						<5> LIVE	897	M	4.8		A
						<6> E.RES					
						<7> LIVE					

LIVE - LIVE FETUS
DEAD - DEAD FETUS

E.RES - EMBRYONIC RESORPTION
F.RES - FETAL RESORPTION

W - WILSON SLICING TECHNIQUE
A - ALIZARIN RED S SKELETAL STAINING TECHN.

CONTENTS OF UTERUS (PLAN VIEW)
GROUP 4 (100 MG/KG)

CORPORA LUTEA L/R	FETUSES LEFT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/ W	IMPLANTATION SITES <POS. IN UTERUS>			FETUSES RIGHT HORN IDENT	SEX	WEIGHT (GRAM)	ANOM. MALF.	A/ W
FEMALE 97													
3/9	898	F	4.7		A	LIVE	<1>	LIVE	900	F	4.5		A
	899	F	4.8		W	LIVE	<2>	LIVE	901	M	2.4		W
						E.RES	<3>	LIVE	902	M	3.8		A
							<4>	LIVE	903	M	3.1		W
							<5>	LIVE	904	F	4.4		A
							<6>	F.RES					
							<7>	F.RES					
							<8>	LIVE	905	F	3.9		W
							<9>	LIVE	906	F	4.4		A
FEMALE 98													
7/6	1032	F	4.9		A	LIVE	<1>	LIVE	1038	M	5.4		A
	1033	F	4.7		W	LIVE	<2>	E.RES					
	1034	F	3.3		A	LIVE	<3>	LIVE	1039	F	5.1		W
	1035	F	5.3		W	LIVE	<4>	LIVE	1040	F	4.9		A
	1036	F	4.6		A	LIVE	<5>	E.RES					
	1037	F	5.2		W	LIVE	<6>						
						E.RES	<7>						
FEMALE 99													
7/6	1041	M	5.2		A	LIVE	<1>	LIVE	1048	F	5.0		W
	1042	M	5.0		W	LIVE	<2>	LIVE	1049	F	5.0		A
	1043	M	5.2		A	LIVE	<3>	LIVE	1050	M	5.5		W
	1044	F	4.5		W	LIVE	<4>	LIVE	1051	F	5.1		A
	1045	F	4.9		A	LIVE	<5>	LIVE	1052	F	4.9		W
	1046	M	5.1		W	LIVE	<6>						
	1047	F	5.0		A	LIVE	<7>						
FEMALE 100													
8/8	1053	M	4.4	M	A	LIVE	<1>	E.RES					
	1054	F	4.3		W	LIVE	<2>	LIVE	1059	M	4.4		A
						F.RES	<3>	LIVE	1060	M	2.8		W
	1055	M	5.4		A	LIVE	<4>	E.RES					
	1056	F	3.9		W	LIVE	<5>	LIVE	1061	F	3.8		A
	1057	F	4.7		A	LIVE	<6>	E.RES					
	1058	F	4.4		W	LIVE	<7>	LIVE	1062	F	3.7		W
							<8>	LIVE	1063	M	5.0		A

LIVE - LIVE FETUS
DEAD - DEAD FETUS
E.RES - EMBRYONIC RESORPTION
F.RES - FETAL RESORPTION
W - WILSON SLICING TECHNIQUE
A - ALIZARIN RED S SKELETAL STAINING TECHN.

RCC PROJECT 236114
SXX 0665 TECHNICAL

Confidential
Copyright by Bayer AG
the use, utilization or distribution
is only permitted with the consent
of Bayer AG.

MATING/NECROPSY SCHEDULE AND INDIVIDUAL NECROPSY FINDINGS

Group 1 (0 mg/kg)

Female No.	Male No.*	Day 0 p.c.	Date of necropsy	Necropsy findings
1	73	April 26, 1989	May 17, 1989	No abnormal findings
2	79	April 26, 1989	May 17, 1989	No abnormal findings
3	85	April 26, 1989	May 17, 1989	White worms in the intestines
4	96	April 26, 1989	May 17, 1989	No abnormal findings
5	97	April 26, 1989	May 17, 1989	No abnormal findings
6	11	April 27, 1989	May 18, 1989	No abnormal findings
7	26	April 27, 1989	May 18, 1989	No abnormal findings
8	39	April 27, 1989	May 18, 1989	No abnormal findings
9	45	April 27, 1989	May 18, 1989	No abnormal findings
10	7	April 28, 1989	May 19, 1989	White worms in the intestines
11	17	April 28, 1989	May 19, 1989	No abnormal findings
12	60	April 28, 1989	May 19, 1989	No abnormal findings
13	66	April 28, 1989	May 19, 1989	No abnormal findings
14	71	April 28, 1989	May 19, 1989	No abnormal findings
15	80	April 28, 1989	May 19, 1989	No abnormal findings
16	86	April 28, 1989	May 19, 1989	No abnormal findings
17	94	April 28, 1989	May 19, 1989	No abnormal findings
18	33	May 1, 1989	May 22, 1989	No abnormal findings
19	62	May 1, 1989	May 22, 1989	No abnormal findings
20	76	May 1, 1989	May 22, 1989	No abnormal findings
21	2	May 3, 1989	May 24, 1989	No abnormal findings
22	14	May 3, 1989	May 24, 1989	No abnormal findings
23	20	May 3, 1989	May 24, 1989	No abnormal findings
24	26	May 3, 1989	May 24, 1989	No abnormal findings
25	27	May 3, 1989	May 24, 1989	No abnormal findings

* = Number of male mated with the female.

RCC PROJECT 236114
SXX 0665 TECHNICAL

MATING/NECROPSY SCHEDULE AND INDIVIDUAL NECROPSY FINDINGS

Group 2 (10 mg/kg)

Female No.	Male No.*	Day 0 p.c.	Date of necropsy	Necropsy findings
26	84	April 26, 1989	May 17, 1989	No abnormal findings
27	93	April 26, 1989	May 17, 1989	No abnormal findings
28	12	April 27, 1989	May 18, 1989	No abnormal findings
29	19	April 27, 1989	May 18, 1989	No abnormal findings
30	22	April 27, 1989	May 18, 1989	Non-pregnant; no abnormal findings
31	33	April 27, 1989	May 18, 1989	No abnormal findings
32	46	April 27, 1989	May 18, 1989	No abnormal findings
33	57	April 27, 1989	May 18, 1989	No abnormal findings
34	58	april 27, 1989	May 18, 1989	No abnormal findings
35	63	April 27, 1989	May 18, 1989	No abnormal findings
36	74	April 27, 1989	May 18, 1989	No abnormal findings
37	77	April 27, 1989	May 18, 1989	No abnormal findings
38	78	April 27, 1989	May 18, 1989	No abnormal findings
39	1	April 28, 1989	May 19, 1989	No abnormal findings
40	15	April 28, 1989	May 19, 1989	No abnormal findings
41	32	April 28, 1989	May 19, 1989	No abnormal findings
42	51	April 28, 1989	May 19, 1989	No abnormal findings
43	53	April 28, 1989	May 19, 1989	No abnormal findings
44	98	April 28, 1989	May 19, 1989	No abnormal findings
45	42	May 1, 1989	May 22, 1989	Non-pregnant; uterus containing fluid
46	46	May 1, 1989	May 22, 1989	White worms in the intestines
47	57	May 1, 1989	May 22, 1989	White worms in the intestine
48	3	May 3, 1989	May 24, 1989	No abnormal findings
49	7	May 3, 1989	May 24, 1989	No abnormal findings
50	17	May 3, 1989	May 24, 1989	White worms in the intestines

* = Number of the male mated with the female.

RCC PROJECT 236114
SXX 0665 TECHNICAL

MATING/NECROPSY SCHEDULE AND INDIVIDUAL NECROPSY FINDINGS

Group 3 (30 mg/kg)

Female No.	Male No.*	Day 0 p.c.	Date of necropsy	Necropsy findings
51	72	April 26, 1989	May 17, 1989	White worms in the intestines
52	34	April 27, 1989	May 18, 1989	White worms in the intestines
53	44	April 27, 1989	May 18, 1989	No abnormal findings
54	61	April 27, 1989	May 18, 1989	No abnormal findings
55	62	April 27, 1989	May 18, 1989	No abnormal findings
56	80	April 27, 1989	May 18, 1989	No abnormal findings
57	3	April 28, 1989	May 19, 1989	White worms in the intestines
58	4	April 28, 1989	May 19, 1989	No abnormal findings
59	18	April 28, 1989	May 19, 1989	White worms in the intestines
60	29	April 28, 1989	May 19, 1989	No abnormal findings
61	31	April 28, 1989	May 19, 1989	White worms in the intestines
62	37	April 28, 1989	May 19, 1989	No abnormal findings
63	44	April 28, 1989	May 19, 1989	No abnormal findings
64	55	April 28, 1989	May 19, 1989	No abnormal findings
65	68	April 28, 1989	May 19, 1989	No abnormal findings
66	75	April 28, 1989	May 19, 1989	No abnormal findings
67	83	April 28, 1989	May 19, 1989	No abnormal findings
68	87	April 28, 1989	May 19, 1989	No abnormal findings
69	90	April 28, 1989	May 19, 1989	Non-pregnant; no abnormal findings
70	34	May 1, 1989	May 22, 1989	No abnormal findings
71	77	May 1, 1989	May 22, 1989	White worms in the intestines
72	95	May 2, 1989	May 23, 1989	White worms in the intestines
73	12	May 3, 1989	May 24, 1989	No abnormal findings
74	40	May 3, 1989	May 24, 1989	No abnormal findings
75	43	May 3, 1989	May 24, 1989	No abnormal findings

* = Number of the male mated with the female.

Confidential
Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

MATING/NECROPSY SCHEDULE AND INDIVIDUAL NECROPSY FINDINGS

Group 4 (100 mg/kg)

Female No.	Male No.*	Day 0 p.c.	Date of necropsy	Necropsy findings
76	69	April 26, 1989	May 17, 1989	No abnormal findings
77	81	April 26, 1989	May 17, 1989	No abnormal findings
78	23	April 27, 1989	May 18, 1989	No abnormal findings
79	35	April 27, 1989	May 18, 1989	White worms in the intestines
80	43	April 27, 1989	May 18, 1989	No abnormal findings
81	47	April 27, 1989	May 18, 1989	No abnormal findings
82	54	April 27, 1989	May 18, 1989	No abnormal findings
83	70	April 27, 1989	May 18, 1989	No abnormal findings
84	90	April 27, 1989	May 18, 1989	No abnormal findings
85	92	April 27, 1989	May 18, 1989	No abnormal findings
86	95	April 27, 1989	May 18, 1989	No abnormal findings
87	2	April 28, 1989	May 19, 1989	No abnormal findings
88	5	April 28, 1989	May 19, 1989	No abnormal findings
89	41	April 28, 1989	May 19, 1989	No abnormal findings
90	70	April 28, 1989	May 19, 1989	Non-pregnant; no abnormal findings
91	89	April 28, 1989	May 19, 1989	No abnormal findings
92	91	April 28, 1989	May 19, 1989	No abnormal findings
93	15	May 1, 1989	May 22, 1989	No abnormal findings
94	4	May 2, 1989	May 23, 1989	No abnormal findings
95	5	May 2, 1989	May 23, 1989	No abnormal findings
96	13	May 2, 1989	May 23, 1989	White worms in the intestines
97	22	May 2, 1989	May 23, 1989	No abnormal findings
98	45	May 3, 1989	May 24, 1989	White worms in the intestines
99	19	May 3, 1989	May 24, 1989	No abnormal findings
100	35	May 3, 1989	May 24, 1989	No abnormal findings

* = Number of the male mated with the female.

TABLES AND FIGURES (SUBGROUPS)

DAYS P.C.

FOOD CONSUMPTION (G/ANIMAL/DAY)
SUBGROUP FEMALES



GROUP 1 (0 MG/KG)			
MEAN	20.0	19.5	21.5
ST.DEV.	1.7	1.8	1.2
GROUP 2 (10 MG/KG)			
MEAN	19.5	19.7	21.5
ST.DEV.	1.6	1.1	1.0
GROUP 3 (30 MG/KG)			
MEAN	19.4	19.1	20.6
ST.DEV.	1.8	2.0	1.9
GROUP 4 (100 MG/KG)			
MEAN	19.1	18.3	20.5
ST.DEV.	1.4	1.3	2.1

DAYS P.C.

FOOD CONSUMPTION (G/ANIMAL/DAY)
SUBGROUP FEMALES

GROUP 1 (0 MG/KG)

ANIMAL NUMBER	DAYS : 0-6	6-11	11-16
101	21	18	21
102	20	20	23
103	22	21	23
104	17	17	21
105	20	19	20
106	22	22	23
107	21	22	22
108	18	20	20
109	19	18	20
110 *	19	19	15

Confidential

Copyright by Bayer AG
the use, utilisation or distribution
is only permitted with the consent
of Bayer AG.

GROUP 2 (10 MG/KG)

ANIMAL NUMBER	DAYS : 0-6	6-11	11-16
111	19	18	21
112	20	20	23
113	21	21	22
114	18	19	20
115	22	20	22
116	19	20	22
117	19	19	20
118	22	22	22
119 *	20	20	16
120	18	20	20

GROUP 3 (30 MG/KG)

ANIMAL NUMBER	DAYS : 0-6	6-11	11-16
121	20	18	20
122	18	17	19
123	19	19	21
124	20	20	22
125	19	18	21
126	20	20	21
127	19	17	20
128	17	17	17
129	20	22	21
130	23	23	24

(*) Animal not considered for evaluation

DAYS P.C.

FOOD CONSUMPTION (G/ANIMAL/DAY)
SUBGROUP FEMALES

GROUP 4 (100 MG/KG)

ANIMAL NUMBER	DAYS : 0-6	6-11	11-16
131	18	16	19
132	21	19	22
133	20	18	23
134	19	18	22
135	17	17	16
136	18	18	20
137	18	18	20
138	20	20	22
139	20	19	20
140	21	20	21

RCC PROJECT 236114
SXX 0665 TECHNICAL

DIFFERENCES IN FOOD CONSUMPTION OF DAMS, MEAN (G/ANIMAL/DAY) SUBGROUPS

Group (mg/kg)	Days post coitum 0 - 6 g (%)*	6 - 11 g (%)*	11 - 16 g (%)*
1 (0)	20.0	19.5 (-2.5)*	21.5 (+7.5)*
2 (10)	19.5 (-2.5)**	19.7 (+1.0)* (+1.0)**	21.5 (+10.3)* (±0.0)**
3 (30)	19.4 (-3.0)**	19.1 (-1.5)* (-2.1)**	20.6 (+6.2)* (-4.2)**
4 (100)	19.1 (-4.5)**	18.3 (-4.2)* (-6.2)**	20.5 (+7.3)* (-4.7)**

Group (mg/kg)	Days post coitum 6 - 16** g (%)*
1 (0)	20.5 (+2.5)*
2 (10)	20.6 (+5.6)* (+0.5)**
3 (30)	19.9 (+2.6)* (-2.9)**
4 (100)	19.4 (+1.6)* (-5.4)**

* = Percentages refer to the values of the pre-dosing period.

** = Percentages refer to the values of group 1.

*** = The calculations of food consumption and body weight gain during the treatment period started on day 6 post coitum (immediately prior to the first administration) and ended on day 16 post coitum (approximately 24 hours after the last administration).

BODY WEIGHTS P.C. (GRAM)
SUBGROUP FEMALES



BODY WEIGHTS P.C. (GRAM)
SUBGROUP FEMALES

GROUP 1 (0 MG/KG)

ANIMAL NUMBER	DAYS P.C. : 0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
101	203	205	211	211	219	219	221	221	223	226	233	234	235	237	244	249
102	208	211	215	216	222	223	226	228	230	235	236	245	246	253	255	259
103	217	220	224	228	234	237	244	242	249	251	259	264	268	273	279	285
104	197	194	201	201	209	212	213	214	220	223	226	230	238	237	242	250
105	183	190	190	204	201	203	206	210	212	216	220	220	225	228	234	243
106	199	203	205	212	218	222	224	228	227	234	240	246	250	249	253	266
107	201	201	205	214	215	216	219	225	231	230	234	239	239	247	255	271
108	200	202	205	209	213	218	214	218	223	228	228	236	237	241	247	257
109	201	204	210	215	215	219	223	222	226	229	233	239	244	248	253	265
110 *	204	203	206	214	216	220	223	224	230	230	230	227	223	221	226	234
MEAN	201	203	207	212	216	219	221	223	227	230	234	239	242	246	251	261
ST.DEV.	9.0	8.7	9.4	7.7	9.1	9.1	10.7	9.3	10.1	9.7	11.0	12.2	12.0	12.8	12.5	12.9

GROUP 2 (10 MG/KG)

ANIMAL NUMBER	DAYS P.C. : 0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
111	188	192	196	199	202	205	209	209	210	214	216	224	225	232	236	240
112	198	204	206	207	214	220	222	221	228	232	236	240	241	244	251	258
113	208	215	218	219	229	231	234	234	238	240	249	256	256	261	267	273
114	208	211	212	217	222	223	226	230	235	238	240	242	248	252	256	266
115	207	209	210	218	221	221	223	225	228	236	234	242	247	250	256	268
116	191	196	201	205	205	207	208	208	216	217	218	223	229	229	234	249
117	194	197	199	203	211	211	211	215	218	222	227	228	231	238	242	255
118	205	207	217	224	226	234	229	235	241	243	251	252	253	262	257	278
119 *	214	214	220	221	230	233	232	232	239	242	246	247	242	239	242	245
120	194	194	198	201	204	206	208	209	215	220	224	228	227	234	234	249
MEAN	199	203	206	210	215	218	219	221	225	229	233	237	240	245	248	260
ST.DEV.	7.9	8.3	8.3	9.2	10.1	10.9	10.0	10.9	11.2	10.9	12.6	12.1	11.9	12.3	12.0	12.6

(*) Female not considered for evaluation